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Advisory Council for the Elimination of Tuberculosis 
Centers for Disease Control and Prevention (CDC) 
8 Corporate Square 
Conference Room 1 A/B/C 
Atlanta 
June 4, 2013 
AGENDA  
8:30  Call to Order and Welcome  Dr. Hazel Dean  
Mr. Shannon Jones 
   
8:35 Roll Call Dr. Hazel Dean 
   
DTBE Strategic Vision for 2015 and the Future 
   
8:45 DTBE Strategic Vision for the Future Dr. Kenneth Castro 
   
9:30 Q’s and A’s  
   
   
TB Prevention and Control in Changing Healthcare Environment 
   
9:45 Redefining the Essential Components of an Effective 
TB Program 
Dr. Jon Warkentin 
    
10:15 Q’s and A’s  
   
10:45 BREAK    
   
10:50 TB as it Relates to Affordable Care Act/ 
Implementation of ACA 
Dr. Christine Ho 
   
11:20 Q‘s and A’s  
   
12:00  Lunch on your own  
   
1:00 U.S. Preventive Services Task Force / Assessing 
Evidence for Treatment of LTBI as Prevention 
Dr. Christine Ho 
   
1:20 Q’s and A’s  
   
1:30 Internal ACET Discussions Mr. Shannon Jones 
 Resolutions  
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Drug/Diagnostic Shortages Update 
2:50  Drug/Diagnostic Shortages - Field Perspective Dr. Jennifer Flood 
   
3:00 CDC Activities around Drug/Diagnostic Shortages Dr. Sundari Mase 
   
3:10 Federal TB Task Force – Drug Shortages Report Dr. Sundari Mase 
   
3:15 An update of the Diagnostics Work Group of the 
Federal TB Task Force 
Dr. Michael Iademarco 
   
3:30 Q and A’s  
   
3:45 Break  
   
4:00 Task Order 18 Update and Recommendations Dr. Wendy Thanassi 
   
4:30 Q’s and A’s  
   
4:45 TB Corrections Update  Dr. Jane Carter/Sarah Bur 
   
5:00 Wrap-Up Discussion Shannon Jones 
   
5:30 Meeting Adjourned  
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Advisory Council for the Elimination of Tuberculosis 
Centers for Disease Control and Prevention (CDC) 
8 Corporate Square 
Conference Room 1 A/B/C 
Atlanta 
June 5, 2013 
AGENDA 
8:30  Call to Order Dr. Hazel Dean  
Mr. Shannon Jones 
   
8:35 Roll Call Dr. Hazel Dean 
   
TB in the Homeless  
   
8:45 HRSA perspectives on the Homeless  Dr. Seiji Hayashi 
    
9:00 Healthcare for the Homeless Mr. John Lozier 
   
9:15 Qs and As  
   
U.S./Mexico Border Health 
   
9:45 TB efforts along the U.S./Mexico Border   Mr. Paul Dulin  
   
10:10 Q’s and A’s  
   
10:30 BREAK  
   
Business Session 
   
10:45 Motion to accept minutes of March 5, 2013 meeting 
Dates for next ACET meeting 
-December 3-4, 2013 
Mr. Shannon Jones 
   
Potential Business Items 
   
10:55 Potential Business Items: 
-Strategy for First and Second Line Drug Shortages 
-Number of meetings – reduce to 1 in person and 2                                      
webinars 
-Number of Liaisons and Ex-Officios 
-Travel of Liaisons and Ex-Officios 
 
Mr. Shannon Jones  
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Continuation of Potential Business Items:  
-Future dates for the ACET meetings 
-Future Agenda Items / What are Priority issues for                   
ACET? 
-Other Business 
   
12:00 Boxed Lunch  
   
12:25 Continuation of Business Items  
   
2:05 Potential agenda topics for the next meeting Mr. Shannon Jones  
   
2:20 Public Comment  
   
2:30 Meeting Adjourned                 
ADVISORY COUNCIL FOR THE ELIMINATION OF TUBERCULOSIS 
CENTERS FOR DISEASE CONTROL AND PREVENTION 
8 Corporate Square 
Conference Room 1 A/B/C 
Atlanta 
June 4-5, 2013 
DRAFT Minutes of Meeting 
The Centers for Disease Control and Prevention (CDC), National Center for 
HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP) Division of 
Tuberculosis Elimination (DTBE) convened a meeting of the Advisory Council for 
the Elimination of Tuberculosis (ACET) on June 4-5, 2013, in Building 8 of CDC’s 
Corporate Square Campus, Conference Room A/B/C, in Atlanta, GA. 
TUESDAY, JUNE 4, 2013 
CALL TO ORDER AND WELCOME 
Shannon Jones, III 
ACET Chair, Deputy Director, City of Austin/Travis County Human Services 
Department 
 
Mr. Jones called the meeting of the ACET to order, at 8:40 AM on Tuesday, June 
4, 2013.  The proceedings were turned over to Dr. Hazel Dean, for 
announcements and roll call. 
 
Hazel D. Dean. ScD. MPH 
Deputy Director, NCHHSTP, CDC, ACET Designated Federal Officer  
 
Dr. Dean reminded the group that all ACET meetings are open to the public, and 
all comments made during the proceedings are a matter of public record.  She 
asked ACET members to be mindful of potential conflicts of interest identified by 
the CDC Committee Management Office (CMO), and instructed them to recuse 
themselves from participating in voting or discussion on matters with which there 
are conflicts of interest.  She requested that ACET members declare any 
potential conflicts of interest to be noted for the record.   
 
Dr. Dean welcomed the following individuals: 
 
 Dr. Edward Desmond, sitting in for Liaison Representative Dr. Jennifer 
Rakeman of the Association of Public Health Laboratories 
 Dr. David Trump, Liaison Representative for the Council of State and 
Territorial Epidemiologists (CSTE) 
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 Dr. Gudelia Rangel, Acting Liaison Representative to replace Dr. Zorrilla, 
Former Executive Secretary of the U.S.-Mexico Border Health 
Commission 
 Dr. Paul Dulin, sitting in for both the U.S.-Mexico Board of Health 
Commission 
 Dr. Edward (Howard) Najoo, Liaison Representative from the Public 
Health Agency of Canada 
 Mr. David Bryden, Liaison Representative replacing Ms. Jennifer Maurer 
from RESULTS 
 
The following ACET Members will rotate off, as of June 30, 2013: 
 
 Mr. Shannon Jones, III, ACET Chair 
 Dr. Masahiro Narita, ACET Member 
 Dr. Barbara Seaworth, ACET Member 
 Dr. Susan Dorman, ACET Member 
 
A nomination package was submitted to the CDC CMO on January 17, 2013 to 
replace the above-mentioned members.   
 
Dr. Dean conducted a roll call of members, ex officio members, and liaison 
representatives.  Quorum was present and no conflicts of interest were declared. 
 
Mr. Shannon Jones 
 
Mr. Jones welcomed participants to the meeting and acknowledged the presence 
of Acting Center Director, Dr. Rima Khabbaz.  Dr. Khabbaz greeted the 
committee and provided brief comments.  The division is making progress in 
identifying a permanent center director.  Individuals are currently being vetted.  In 
addition, CDC is under significant budgetary constraints due to the sequestration 
and budget reductions.  Not only have activities and programs been affected but 
also travel, which has restricted some staff from participating in meetings. Yet, 
there is still exciting work occurring in DTBE.   
 
Individuals participating via the phone were asked to identify themselves.  The 
following were present: 
 
 Ms. Cornelia Jervis, Treatment Action Group 
 Ms. Demetria Gardner, Management Analysis and Services Office 
(MASO) 
 Mr. Eddie Hedrick, Association for Professionals In Infectious Control and 
Epidemiology 
 Dr. Mamodikoe Makhene, National Institutes of Health 
 Dr. Sheldon Morris, Food and Drug Administration (FDA) 




Advisory Council for the Elimination of Tuberculosis 
Centers for Disease Control and Prevention 
June 4 - 5, 2013   
3 
 
Observers were also given the opportunity to introduce themselves.  [See 
Attachment #1 for a full list of attendees.] 
 
DTBE STRATEGIC VISION FOR 2015 AND THE FUTURE 
 
DTBE Strategic Vision for the Future 
Dr. Kenneth Castro 
Director, DTBE 
 
Dr. Castro’s presentation outlined the 2015 strategic vision, for DTBE.  The 
DTBE webpage, www.cdc.gov/tb/about/strategicplan.htm, highlights the strategic 
plan and lays out the priorities, goals, and core functions of DTBE.  Also included 
are overviews of past activities, plans, and reports.  The strategic planning 
sessions were started back in 1989.  Public Law 110-392 authorizes the division 
through 2013.  In examining the law, gaps between what was authorized and 
what has been received from Congress can be easily identified; therefore, 
Congress is considering redrafting Public Law 110-392. 
 
DTBE’s vision is a nation and world free of TB.  The mission is to promote health 
and quality of life by preventing, controlling, and eventually eliminating 
tuberculosis from the United States, and by collaborating with other countries and 
international partners in controlling global tuberculosis.  The priorities are to 
prevent new cases of infection and disease with s; find and cure all persons with 
TB disease; reduce tuberculosis in foreign-born persons residing in, or traveling 
to, the United States; reduce TB in U.S. racial and ethnic minority populations; 
reduce impact of multidrug-resistant and extensively drug-resistant TB in the U.S. 
and abroad; and reduce HIV-associated TB in the U.S. and internationally. Many 
of the priorities were developed, because of the work in Africa, through the 
President’s Emergency Plan for AIDS Relief (PEPFAR). 
 
Several core functions have been identified for the division.  They are as follows: 
 Conduct routine surveillance (including drug susceptibility surveillance) 
and periodic surveys 
 Provide funding and technical assistance to state and local programs for 
case finding, contact investigation, and completion of treatment, and 
support care and treatment with assistance from Regional Training and 
Medical Consultation Centers (RTMCC)  
 Support intramural infrastructure (salaries, travel, equipment and supplies) 
required for maintaining subject-matter expertise in TB  
 Guide preparedness and outbreak investigation responses  
 Conduct program evaluation (e.g., National TB Indicators Project)  
 Provide laboratory diagnostic services, research and build/maintain 
capacity  
 Provide data management, statistical, and IT support 
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 Obtain external expert consultation and advice to ensure that research 
and program activities are responsive to emergent public health concerns  
 Conduct critical, programmatically relevant operational research to 
develop and evaluate new tools/interventions for diagnosis, drug 
treatment, prevention and control of TB (to help programs work more 
effectively and more efficiently)  
 Develop and evaluate evidence-based training and educational materials, 
policies, and guidelines to ensure competency in TB diagnosis, drug 
treatment, laboratory capacity, and programmatic prevention and control   
 Develop education, risk, and media communications (web and print 
based) to aid in preparedness and public awareness of TB prevention and 
control  
 Cultivate strategic partnerships (e.g., Stop TB USA, NTCA, ATS, IDSA, 
AAP, APHL, affected individuals and their families), across other federal 
agencies (FTBTF), US-MX Binational Commission, NHCHC*,NCCHC*, 
global Stop TB Partnership 
 
Below is a pie chart and graph, which were presented to illustrate the budget and 
funding for DTBE. 
 
• Intramural expenditures include salary and benefits, direct assistance (38 domestic 
FTEs  and 4.5 international FTEs for field support), software licenses, maintenance 
agreements, communication, printing, supplies, travel, and miscellaneous expenses
• Cooperative Agreements include funds for prevention and control, laboratory 
support, training centers and human resource development, partnerships
• Extramural contracts mostly include research consortia,  laboratory genotyping, 
communication campaigns
FY 2012 DTBE Budget, by Categories($143,796,458*)





Advisory Council for the Elimination of Tuberculosis 
Centers for Disease Control and Prevention 




About three quarters of the budget goes to cooperative agreements and 
extramural contracts.   Over time, the division has worked diligently to make the 
funding follow the epidemiology of TB.  By working with partners, an agreement 
was met to redistribute funding.  Funding has shifted starting in 2013 and a 
performance-based component has been added, which looks at completion of 
therapy and the number of culture positive individuals who have drug 
susceptibility tests.  The hope is to redistribute 60% of the budget by 2013, 80% 
by 2014, and all budgetary assignments to be formula-based by 2015.   
 
There are several challenges or threats to the 2013-2015 efforts.  Some of the 
challenges include budget sequestration and mandated reductions, weakened 
programs, outbreak response capacity, and drug shortages.  However, there are 
also several opportunities for DTBE, like the Affordable Care Act (ACA) coverage 
for TB services, U.S. Prevention Services Taskforce (USPSTF) to review TB 
screening guidelines, increases in federally-qualified and community health 
centers, and a universal genotyping role in targeting prevention and control 
efforts.   
 
The proposed strategic vision for tuberculosis is to retain optimistic goal of TB 
elimination (≤ 1 case/million) in U.S. and advance global prevention and control; 
bridge implementation, knowledge, and ambition gaps, and focus activities to 
address specific “change factors”.  Much of the work was started earlier and in 
May 2011, the Restructuring the U.S. Tuberculosis Program Work Group Report 
Percent of TB Prevention & Control Funding 
Formula Redistribution, FY 2004 – FY 2015
Original TB funding formula 
implemented FY 2005
Fiscal Year (FY) Goal: Redistribute all TB funds based on 
formula to align with data-driven 
epidemiologic needs and performance
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was shared with ACET.  The work group ratified the broad areas of work that 
DTBE undertakes and determined that the division needed to retain the 
cooperative agreements.  Program relevant research and global/international 
activities was also endorsed, and there was an acknowledgement of the need to 
the support workforce (subject matter experts, SMEs). 
 
Dr. Castro gleaned lessons learned from the Smallpox and Its Eradication 
document.  Some of those lessons were outlined for the committee. 
 
1. Political commitment, coordination, and implementation 
• Decision by 1959 WHA, ratified in 1966 WHA with new resources 
2. Special program 
• Specifically targeted (cessation of mass vaccination), time-limited  
• Adapted to local epidemiology and different local conditions 
• Identify and address set-backs 
3. Defined objectives and goals 
• Complete disease reporting and nil incidence 
• Discover cases and contain outbreaks within 2 weeks 
4. Quality control and program management 
• Network of professional staff:  “many thousands of  health staff 
received training in the execution of vaccination programs and in 
field epidemiology”  
5. Research 
• Better methods for quality vaccine production and targeted delivery 
6. Certification,  Costs 
 
Dr. Castro has taken the above lessons and applied them to TB elimination, 
which result in the following outline of activities: 
 
1. Political commitment, coordination, and implementation 
• Reauthorize and resource PL110-392 
• Develop and nurture strategic alliances (including affected persons) 
2. Special program (demonstrate added value to PPACA) 
• Active case finding adapted to local epidemiology, targeted contact 
investigations, work with federally-qualified health centers (FQHC), 
shelters, corrections, refugee programs, recent immigrants 
(students, workers), electronic lab records. Focus on universal 
diagnosis and cure 
• Provide timely and robust emergency outbreak response capacity 
• Rely on molecular genotyping to target contact investigations, 
informed by infectious periods and exposed cohorts 
• “Allocate resources where needed,” such as high-burden areas, for 
targeted screening of high risk groups; cease mass screening of all 
students, teachers, healthcare workers (HCW) 
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• Develop early warning system and mechanisms to prevent 
commodity shortages (drugs, lab and other diagnostic tests) 
• Align domestic work in support of global TB prevention and control 
3. Defined objectives and goals 
• Complete disease reporting and incidence of ≤ 1/million 
• Define interim measures 
• Targeted testing and treatment of high-risk groups with LTBI (HIV-
infected, persons on TNF-alpha inhibitors, recent immigrants from 
high-burden countries) 
4. Quality control and program management 
• Network of trained professional staff  with subject-matter expertise 
• Identify and address set-backs by reliance on, and refinements of, 
indices in NTIP 
5. Research 
• Invest in new tools research (i.e., same-day diagnosis of disease 
and LTBI, drug resistance, and short course Rx for disease and 
LTBI) 
6. Certification,  Costs 
• Calculate averted cases, cost savings, and societal benefits 
 
The above activities has caused the division to consider revising and updating 
the tuberculosis targets and measures in order to achieve ambitious but realistic 
goals that will aid in achieving its mission.  The division should aim for elimination 
of ≤1 case/million by 2050 and develop interim targets, like 1/100,000 by 2020, 
5/million by 2030, 2.5/million by 2040 or maybe even zero TB deaths.  In order to 
eliminate recent transmissions, DTBE should develop quantitative measure of 
recent transmission and identify interim targets for elimination of transmission.  In 
addition, it should calculate cases and deaths averted, as a metric. 
 
Dr. Castro concluded the presentation by posing several questions to ACET that 
the division needs guidance around: 
 
 Is the national comprehensive TB elimination framework appropriate and 
relevant to attain maximal impact? 
o What proportion of CDC resources should support future program 
(prevention and control) laboratory, RTMCC, human resource 
development, research, global work? 
o Continue with formula funding plans in near future? 
 Recommendations for program monitoring and improvement? 
 Recommendations for outbreak response capacity? 
 What type of research should be supported by CDC? 
 Is the alignment of domestic and global work appropriate?  Recommended 
revisions? 
 




Advisory Council for the Elimination of Tuberculosis 
Centers for Disease Control and Prevention 
June 4 - 5, 2013   
8 
Dr. Baine did not notice any new activities proposed for Priority 3, which is to 
reduce tuberculosis in U.S. racial and ethnic minority populations.  Dr. Castro 
said a number of racial and ethnic populations are supported with funding.  
Beyond that, DTBE needs to better understand the social determinants of health 
that are accounting for disparities.  Although TB incidences have decreased, 
there still exists a significant gap for minorities, and that needs to be addressed.  
Better collapsed approaches are also needed for homeless shelters and 
correctional facilities. 
 
Dr. Horsburgh noted the proposal to the USPSTF has the potential to be 
extremely cost effective by providing funding to perform one of the major 
interventions and incentivize physicians to carry out the intervention.  Yet, the 
materials indicate that the proposal is at risk.  Dr. Castro was pleased to report 
that the proposal would be funded.  Atlanta Human Resources Center (AHRC) is 
funding $125,000 and DTBE $375,000. Once, DTBE knew its budget, the 
proposal was the first thing funded. 
 
Dr. Reichman urged DTBE to make very evident the activities that it is doing well.  
The outbreak response is an example of an activity that should be spotlighted.   
Stop TB USA shows an average of two or three outbreaks per week in the United 
States, and the outbreaks do get media attention.  The media attention would 
provide a platform to bring awareness to ongoing TB threats from international 
cases.  DTBE staff should learn to respond to these opportunities, which can 
offer the U.S. realistic pictures of TB in 2013.  Dr. Castro agreed with Dr. 
Reichman’s thought, but he has found that local health departments do not want 
to draw attention, in that regard.  The biggest misconception in this country is that 
TB is a disease of the past.  This is why it is key to continue to work with affected 
populations to give them a voice and a platform.  More over, when DTBE meets 
with CSTE, state, and territorial health departments, rarely is TB on the agenda 
because health departments are doing pretty well in those efforts.   Health 
departments should be encouraged to celebrate their work, which can help to 
dispel the belief that TB is no longer a threat for the United States.  
 
Dr. Hewitt made a comment in regards to Dr. Castro’s smallpox correlation.  
Tuberculosis elimination needs to be a politicized activity by people outside of 
CDC, who have a stake.  Public health is more political than it was 20 years ago, 
and will continue to become more political, if the tension between acute care and 
primary care continues to become grayer.  He hopes the Affordable Care Act 
would address that. On the subject of social determinants, the Substance Abuse 
and Mental Health Administration (SAMHA) found that it did not have the 
resources to address the social determinants of health that drive the issues in 
racial and ethnic populations.  In addition, that fact should be put into context; 
moreover, activities should be identified to bring about immediate impact.  
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Mr. Jones asked Dr. Castro to speak on emergency response where cooperative 
agreements may not be implemented and efforts to address social determinants 
of health if cooperative agreements were reprioritize among states.  Dr. Castro 
replied in any jurisdiction where the annual incidence of TB is less than 10 per 
year, DTBE could consider working with other partners.  The division could also 
redistribute funding in order to fund partners who are more pluripotential, so that 
in the event of a cluster of TB threats, there is ready access to call for help and 
for CDC to mobilize as well as other partners.  Surveillance, he noted, should 
never stop.  He would personally enter cases by hand if needed because the 
moment surveillance stops, decision markers are given an opportunity to make 
excuses for not supporting efforts and providing resources.  He welcomed input 
on how to modify and move forward.   If data shows that DTBE is not moving in 
the right direction, it will reassess and try again. 
 
Dr. Benjamin suggested lessons learned should also be gleaned from HIV efforts 
as well and Ms. Levin highlighted the need for more coordination with 
correctional facilities and detention centers, with a focus on the transient issues.  
Dr. Castro agreed that efforts have fallen significantly in that area and should be 
strengthened.   
 
Dr. Baine asked where is the evidence that all the determinants are social and 
what is the prevalence required in the U.S. population to have a lower threshold 
for positivity and screening.  Dr. Castro answered the data that support the 
various threshold have to do with retest probability.  U.S-born populations are 
more likely to have a positive skin test because of a cross reactor non-TB 
bacteria or a false positive reactor.  That is why the thresholds were changed.   
The thresholds were put into place before Dr. Castro’s time in the division.  He 
suggested the necessity for population-specific thresholds.   
 
Dr. Andy Vernon provided some statistics to ACET concerning incarceration.  
Internal analysis shows that the best predictor of failure to complete treatment is 
being diagnosed while incarcerated; more so than being homeless or a racial or 
ethnic minority. Twenty-five percent of U.S. cases diagnosed while incarcerated 
fail to complete treatment at all. 
 
TB PREVENTION AND CONTROL IN CHANGING HEALTHCARE ENVIRONMENT 
 
Redefining the Essential Components of an Effective TB Program  
Dr. Jon Warkentin 
President, National Tuberculosis Controllers Association (NTCA), State TB 
Control Officer, Tennessee 
 
Dr. Warkentin reviewed the Morbidity and Mortality Weekly Report (MMWR) 
entitled Essential Components of a Tuberculosis Prevention and Control 
Program, which he attributes to playing a major role in his work, in Tennessee 
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when he was an administrator for the TB program.   The report was published on 
September 8, 1995 and comprised the recommendations of ACET, at that time.   
 
The purpose of the document was to provide a national standard for the 
assessment of individual TB control programs by TB control program managers, 
policymakers, and other persons evaluating TB programs.  It was also to assist 
local programs in obtaining and maintaining adequate resources for TB control 
activities, define the essential components of a TB control program, and 
emphasize the importance: 
 
 Prioritizing TB control activities (3 strategies)  
 Coordinating care with other health-care providers, facilities, and 
community organizations; and  
 Using alternative approaches to TB control, e.g.: 
o The expanded use of directly observed therapy 
o Targeted screening and prevention programs to high-risk populations, 
and  
o Adoption of current recommendations for the treatment of TB  
 
Although the size and structure of TB control programs vary according to each 
community’s specific needs, TB control program managers should attempt to 
incorporate each of the core components into program activities.  However, the 
question is where is it done that way.  It does happen in some areas but still 
certain essential components are no longer feasible. How have sociopolitical 
changes influenced the application of this recommendation in state and local 
health departments’ TB programs?   
 
Dr. Warkentin provided an outline derived from the Essential Components 
document.  Below is the outline he uses to guide his work and shares with his 
staff.   
 
I. Overall planning and policy 
A. Overall TB control strategy and written policies and procedures 
B. Advising local institutions and practitioners 
C. Appropriate laws and regulations to support TB control activities 
D. Adequate and appropriate staff to conduct TB control activities 
E. Adequate funding to conduct TB control activities 
F. Networks with community groups 
 
II. Managing persons who have disease or who are suspected of having 
disease 
A. Clinical services  
B. Developing a treatment plan 
C. Clinic services 
D. Promoting adherence 
E. Referral system for other medical problems 
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F. Clinical consultative services 
G. Inpatient care 
H. Confinement capability 
I. Infection control 
J. Coordinating care with other health-care providers and facilities 
 
III. Identifying persons who have clinically active TB 
A. Diagnostic methods 
B. Case finding 
C. Contact investigation 
 
IV. Identifying and managing persons infected with Mycobacterium 
tuberculosis 
A. Close contacts of persons known or suspected to have TB 
B. Persons infected with HIV 
C. Persons who inject illicit drugs or other locally identified high-risk 
substance users (e.g., crack cocaine users) 
D. Persons who have medical risk factors known to increase the risk 
for disease if infection occurs 
E. Residents and employees of high-risk congregate settings (e.g., 
correctional institutions, nursing homes, mental institutions, other 
long-term residential facilities, shelters for the homeless) 
F. Health-care workers who serve high-risk clients 
G. Foreign-born persons, including children, recently arrived (within 5 
years) from countries that have a high TB incidence or prevalence 
H. Some medically underserved, low-income populations, as defined 
locally 
I. Infants, children, and adolescents exposed to adults in high-risk 
categories 
 
V. Laboratory and diagnostic services 
A. Chest radiograph and interpretation 
B. Mycobacteriology laboratory 
C. Diagnostic services to assess drug toxicity 
D. HIV testing and counseling 
 
VI. Data collection and analysis  
A. Case reporting 
B. TB registry 
C. Protection of confidentiality 
D. Drug resistance surveillance  
E. Data analysis and program evaluation 
 
VII. Training and education 
A. Staff training 
B. Education for health-care providers and members of the community 
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The outline has helped his agency to develop a scope of services for metro 
programs and serves as an auditing tool based on each of the components. They 
have also developed a 72-point action plan and set measurable objectives using 
each of the components.  This helps to tie in performance metrics and assists in 
making programs more effective. 
 
Dr. Warkentin suggests revisiting the document in light of technology, 
epidemiology and sociopolitical changes.  The outline can highlight: 
 What needs to be updated? 
 Are there additional components needed? 
 How is public health practice changing at the state and local level? 
 What is the federal (CDC/DTBE) role? 
 What should ACET do? 
 
There have been numerous changes in technology, like internet, social media, 
mobile communication devices, data management, genotyping, molecular drug 
sensitive testing, etc, but what has not changed are things like, TB Vaccine, 
HRZE (antituberculosis drug), and isoniazid (INH) as the leading treatment for 
infections.   
 
Epidemiology changes include U.S. total TB cases at a historical low, proportions 
of foreign born cases increasing, HIV/TB co-infections are somewhat stable, and 
multi-drug and extreme-drug resistance (MDR, XDR) globally are rampant, but 
MDR-TB in the U.S. is low.  What have not changed are issues like cases of TB 
in correction facilities, homelessness, drug abuse, and alcoholism. 
 
There have been several sociopolitical changes.  Dr. Warkentin listed the 
following: 
 Post-911 era: Mtb as a potential BT threat, prioritization of public funds for 
“security” 
 National economy: robust economy to worst recession since the 1930’s to 
slow “recovery” 
 Focus on deficit reduction 
 Progressive and additive budget cuts to PH at local, state and national 
levels  
 Restructuring of state health departments challenges continuity of TB 
program initiatives 
 ACA - Rapidly changing health-care services environment, shifting 
organizational roles 
 Evolving details and impact of  “sequestration” for FY2013, FY2014 and 
beyond 
o Cuts to “Cooperative Agreements” and contracts with states, big 
cities, partner organizations, domestic research consortia 
 Unclear national commitment to the goal of domestic TB elimination 
(DHHS, CDC, DTBE?) 
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 Shortages of anti-TB drugs and biologics: INH, Tubersol, Aplisol, 
injectables, third-line drugs 
 “The cycle of neglect” --- again?! 
 
Moving ahead, there is an urgent need to define and claim the roles of public 
health in local, state, and national TB control and prevention.   The division 
needs to assess the relevance of the 1995 Essential Comments document and 
update areas in light of changes since its inception and identify new components 
needed.    It is also necessary to update the TB prevention and control 
guidelines, define the role of CDC/DTBE with regard to assessment and policy 
development, and determine if there is a new national TB prevention and control 
paradigm emerging. 
 
Dr. Warkentin referenced another smallpox model that could be used called On 
Fire, the Fight to Eradicate Smallpox by Bill Fahgee.  It too contains lessons 
learned that should be examined to locate some parallels and points of 
divergence for TB work.   He offered a word of caution that the model needs to 
be evaluated, thought through thoroughly, and discussed with partners before 
plunging into a new paradigm.  A list of several potential partners was presented.   
 
Before closing, he acknowledged several individuals who helped with the 
presentation. 
 
Mr. Jones opened the floor for discussion.  
 
Dr. Dorman fully supported the idea of revising the document and said ACET has 
a very clear and necessary role in helping to advise DTBE as ACA becomes 
implemented.  She pondered if the goal of TB elimination, considering the current 
sociopolitical condition, should be what ACET and DTBE strive for and maybe 
reengaging the topic would be useful.  Dr. Warkentin has also pondered the 
same thoughts.  Social determinants of health are key to dealing with this issue 
but are very resource-dependent.   
 
Dr. Levin’s comments were around the homeless and drug-using population.  
Expecting treatment without providing management of the addiction at the same 
time is unrealistic.   There need to be collaboration between TB control programs 
and providers, who work with addiction.  This could increase compliance, if 
services were offered together.   Dr. Hewitt added that drug use has changed 
and therefore assumptions of drug use should be revisited, as well.   The number 
of drug injectors has declined, and there are new methods of drug use.  Changes 
can also be seen in the homeless population makeup.  These are additional 
elements in the document that should be updated.   Dr. Warkentin also included 
the growing number of veterans some of which are receiving organ transplants.  
Dr. Desmond recalled there was no mention of genotyping in the document, 
nucleic acid amplification (NAA), or molecular detection of drug resistance.  He 
went on to say genotyping requires that the state public labs acquire the cultures.  
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There is a role for the TB control program to ensure cultures are acquired, that 
good regulations are in place, and follow-up occurs.  He expressed 
disappointment in the nucleic acid amplification testing and how poorly it is has 
penetrated into routine practices.  TB programs could also encourage the use of 
NAA testing among clinicians.  Dr. Warkentin responded many hospitals ship 
their specimens to large labs out of state, which puts reflex testing with NAA up 
in the air. There is delay in culture confirmation and drug sensitivity testing, which 
are both avoidable.  Dr. Elson said, when culture results do become available, 
they should be conveyed back to where the person is at that time not where they 
were collected.  This would help with the transient issues.   
 
Dr. Burgos called TB a disease of poverty, which is not talked about in the 
document.  Poverty has increased recently in the United States, and although TB 
is not affecting the U.S. right now, down the line it can become a problem 
causing increasing occurrences.  A study of how poverty affects TB rates in the 
future should be studied.   
 
Dr. Baine expressed concern over drugs that are found to be economical 
possibly not being available in the future due to shortages. 
 
Ms. Bur noted changes in correctional facilities, which have seen inmate 
populations more than doubled, since the creation of the document.  The 
document should have a section on corrections and the roles of TB control in 
correctional facilities.   Dr. Elson agreed and added into the list changes in the 
complexity of local jails and detention centers.  Patients in those institutions are 
often referred to emergency rooms, where they are sometimes not evaluated 
properly.  Dr. Warkentin replied the amount of for-profit correctional facilities is 
something different from what was seen in 1995, as well as continuity of care 
while incarcerated.  All those things need to be explored in the new document.   
 
Dr. Doshi inquired if Dr. Warkentin knew the cost of treating a person with active 
TB and if it differed depending on the individual’s ethnicity.  Ms. Marks provided 
some statistics.  Including the half, which are hospitalized, the average cost is 
about $17,000 per drug susceptible case, $131,000 per MDR case, and 
$430,000 per XDR case.  There is a very wide variability on those cases due to 
co-infections.  
 
Dr. Roselle noted there was no reference to collaborating with the general 
population of internist, pulmonary doctors, etc.  There’s always mention of “Public 
Health” in meetings but no one speaks to “public health” and vice versa when he 
attends infectious disease meetings.  Nevertheless, never is it more important for 
the groups to collaborate in light of ACA.  There is a reluctance of interaction.  
Doctors think that Public Health is bothering them unless they are desperate and 
Public Health cannot figure out why doctors are not taking care of business.  The 
result is a self-fulfilling prophesy.  Therefore, he suggested partnership start with 
clinicians, doctors, etc.  Dr. Warkentin agreed and saw the problem to be an 
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uphill battle.  What further complicates the matter is finding someone to provide 
education to both the groups.  
 
Ms. Cole said to consider establishing a type of memorandum of understanding 
(MOU) with providers, in light of decreasing resources.  This will counteract 
fragmentation.  Dr. Castro agreed with Ms. Cole and said currently dialysis care 
is using similar practices.   Ms. Cole suggested that under the ACA, TB clinics 
could be designated as essential service providers.   
 
Mr. Jones before closing for a break, made a change in the agenda.  The 
resolution discussion would be move to later in the day so that elements from 
other presentations, such as drug shortages could be included.  The members 
concurred with Mr. Jones’ suggestion.  He asked members to prepare their 
resolutions over the break.   
 
He group reconvened at 11:05 AM.  Dr. Dean took role and quorum was present.   
 
TB as it Relates to Affordable Care Act/Implementation of ACA  
Dr. Christine Ho 
Medical Officer, DTBE, CDC 
 
Dr. Ho’s presentation was entitled The Impact of Patient Protection and 
Affordable Care Act on Tuberculosis.  The purpose of the presentation was to 
dissect the Affordable Care Act into simple terms, describe its impact on TB 
control, the role of TB programs, and how programs could strategically leverage 
opportunities presented by the law to ensure TB services.   
 
The ACA now allows adult children 26 and under to be covered by parents’ 
plans, which will account for 3.1 million newly covered individuals.   It also will 
expand coverage to many currently uninsured persons.  Because of expanded 
coverage: 
 Uninsured non-elderly will drop by 20 million in 2015 
 Medicaid is expanded to individuals with incomes below 133% the federal 
poverty level (FPL) for participating states 
 Enrollment for private insurance plans will be available through the 
Marketplace, or Exchanges (+13 million) 
 Employer and non-group coverage (-5 million) 
 
It also offers new consumer protections and choices.  ACA generally prohibits 
denial of coverage based on pre-existing conditions and rescission (dropping 
coverage retroactively).  It bans lifetime and annual coverage limits, puts 
restrictions on out-of-network ER usage, and expands consumers’ rights to 
appeal denials.     
 
States have the opportunity to expand Medicaid eligibility to adults ages 19 – 64 
with incomes up to 133% of the (FPL) ($15,282/year for an individual, 
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$31,322/year for a family of 4) and 100% federal funding through 2016, 90% 
thereafter.  States have no deadline for implementing the expansion.  There will 
be one streamlined application for Medicaid and private health plans in the 
Marketplace and a shift to a simplified way of calculating income to determine 
Medicaid/CHIP eligibility.  This calculation is known as the Modified Adjusted 
Gross Income (MAGI).  There will be the opportunity for employers and 
individuals to directly compare plans through the Exchange, or Marketplace. 
 
There will still be 44 million people in 2014 not covered by ACA.  In 2015, there 
will be 37 million and 31 million in 2016.  Therefore, there will still be a need for 
safety-net services.  Areas of convergence should be identified between covered 
services under ACA and the essential components of a TB prevention control 
program in order to leverage opportunities to maximize population health.   
 
Prior to healthcare reform, States could add Medicaid eligibility for TB patients.  
Now, states have the option to extend Medicaid eligibility to low-income persons 
infected with TB.  Dr. Ho provided a list of covered TB-related services, which 
include:  
 Prescribed drugs 
 Physicians’ services (includes outpatient hospital services, rural health 
clinic services, and Federally Qualified Health Center (FQHC) services) 
 Laboratory and X-ray services 
 Clinic and FQHC services 
 Case management services 
 Services (other than room and board) designed to encourage completion 
of outpatient regimens, including services to directly observe the intake of 
prescribed drugs. 
 
Currently, nine states have elected to provide this benefit, including Arizona, 
California, Connecticut, Louisiana, Montana, New York, Oklahoma, Utah, and 
Wyoming.  Receipt of matching federal dollars for treating eligible TB patients 
could alleviate budget difficulties for some states. 
 
Individuals will be enrolled through the “Marketplace”.  The Marketplace (or 
insurance exchanges) will use a website for qualified individuals and qualified 
employers to directly compare private health insurance options also known as 
Qualified Health Plans (QHPs).  The Marketplace provides the advantage of 
directly comparing QHPs based on price, benefits, quality, and other factors.  It 
also helps enhance competition in the health insurance market and increases 
affordability through premium tax credits and cost sharing reductions.  Moreover, 
it ensures quality through requiring that QHPs must meet basic standards, 
including quality standards, consumer protections, and access to an adequate 
range of clinicians.  In addition, the Marketplace makes costs clear by providing 
information about prices and benefits in simple terms consumers can 
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The law requires the following services to be covered without cost-sharing for 
non-grandfathered individual and small group plans as well as Medicaid 
expansion plans: 
 United States Preventive Services Task Force (USPSTF) 
o All preventive services with an ‘A’ or ‘B’ grade recommendation 
o LTBI screening of high risk persons had an ‘A’ grade in 1996 
o 2002 recommendations deferred to CDC, ungraded 
o Ungraded, LTBI screening not covered without cost-sharing 
 Advisory Council on Immunization Practices (ACIP) and Health Resources 
and Services Administration (HRSA)-supported recommendations 
o TB testing for “children at high-risk for TB” 
 
What the law does not state is what additional specific services will or will not be 
covered.  Coverage of specific services will be determined state-by-state.   
States previously established benchmark plans and set the minimum 
requirements for a plan.  They must include these 10 areas (also referred to as 
the 10 Essential Health Benefits): 
 
1. Ambulatory patient services 
2. Emergency services 
3. Hospitalization 
4. Maternity and newborn care 
5. Mental health and substance use disorder services, including 
behavioral health treatment 
6. Prescription drugs  
7. Rehabilitative services and devices 
8. Laboratory services 
9. Preventive and wellness services and chronic disease management 
10. Pediatric services, including oral and vision care    
 
The law requires that QHPs offered through Marketplaces include in their 
networks essential community providers, where available, that serve 
predominately low-income, medically-underserved individuals.  Centers for 
Medicare and Medicaid Services (CMS) regulations provide that a QHP issuer 
must have a sufficient number and geographic distribution of essential 
community providers (ECPs), where available, to ensure reasonable and timely 
access to a broad range of such providers.  The Health Resources and Services 
Administration (HRSA) identified ECPs, which include providers eligible for the 
340B program.  TB programs can be a member of an accountable care 
organization; they can also identify additional hospitals, clinics, practices that 
evaluate and diagnose TB suspects and cases; and ensure these facilities are 
designated as ECP.   
 
Dr. Ho provided an example of Urban County A TB cases: 
 Foreign-born cases 
o Mix of newly arrived and settled immigrants or refugees 
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o Medical services through the refugee clinic, federally qualified 
health center (FQHC), or other community providers 
 US-born cases 
o Concentrated in an area with shelters and treatment facilities 
o One FQHC and several non-profit clinics serve this area 
 Options to optimize TB screening and evaluation: 
o Non-profit clinic affiliates with an accountable care organization 
(academic medical center, consortium) and bill for services 
o TB program partners with FQHC and refugee clinics to do TB 
screening and evaluation, those clinics bill for services 
o TB clinic gets 340B or FQHC status and bills for services 
 
The Meaningful Use Rule is an incentive designed to get physicians and 
clinicians to utilize electronic health records.  It is also another way to track 
performance.  To collective incentives, providers must use structured fields and 
clinical decision support tools.  They must report clinical quality measures and 
communicate relevant health information to patients.  Lastly, providers must 
provide patients the ability to view their health information and provide a 
summary of care record for transitions and/or referrals. 
 
There is a stage in Meaningful Use, where providers will be required to select 
quality measures to report on.  As an example, new or updated HIV measures in 
the endorsement process include: percent of patients seen at least once during 
12-month period with suppressed VL; percent of patients seen at least once 
during 12-month period on ART; percent of patients with a visit every 6 months 
over 24 months; and percent of patients with gap in care over a 12-month period. 
 
Clinical decision support (CDS) is a process for enhancing health-related 
decisions and actions with pertinent, organized clinical knowledge and patient 
information to improve health and healthcare delivery.   The systems provide 
prompts to the provider for retention/re-engagement in care; patient self-care and 
treatment adherence; data collection and bi-directional reporting and 
communicating; and performance measurement and improvement 
 
What may also be impacted by the ACA is billing.  Right now, the health 
departments provide services to clients regardless of ability to pay.  There will 
now be other options available.    Option 1 is the health departments continue to 
provide clinical services to clients.  For insured clients, health departments may 
bill those health plans for services.  In Option 2, the insured patients can receive 
services from non-health department providers.  The health department in that 
option cares for the uninsured clients only, but with that option, they are not able 
to ensure quality services for outside providers.   
 
Several billing resources exist that can be considered for TB such as: 
 National Center for Immunization and Respiratory Diseases (NCIRD) 
American Recovery and Reinvestment Act-funded billing project 
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 2012 NTCA  Billing roundtable session 
 CDC and billing activities 
 American Health Insurance Plan (AHIP) has 3-part billable project to 
support sites (not known whether this will need MOU or workaround) 
o Contracting 
o Coding 
o Credentialing  
 National Association of City and County Officials (NACCHO) developed a 
billing toolkit 
 
There is a continued role for public health under the ACA for populations most at 
risk for TB, such as non US-born, racial or ethnic minorities, homeless, and 
persons affected by alcohol or substance abuse, who have limited access to 
health care.  Ongoing transmission, outbreaks, and drug resistance can result, if 
contacts of infectious patients are not located and provided preventive therapy or 
if persons with TB disease are not treated completely.  Guarantees for inherently 
governmental public health services were not the goal of the law, and the 
Affordable Care Act expansion will not substantially decrease the need for these 
services by CDC and health department partners. 
 
There are several ways to leverage TB services in the community, like studying 
each state’s benchmark, or alternative plan (upon which the minimum required 
coverage is based) to address what is and is not covered.  Addition suggests are 
to identify health plans that serve populations at high-risk for TB and working with 
those plans directly to cover TB-related patient services (such as LTBI 
treatment).  Other recommendations would be to identify providers that serve 
individuals at high-risk for TB; explore partnership with these providers, and 
survey future education and quality assurance opportunities in these settings. 
 
The floor was opened for discussion. 
 
Dr. Hewitt asked if TB drugs were included in the formularies and if cost sharing 
was included in prescription drugs. Dr. Ho said it could be, under the alternative 
plan, and it is only for preventative services that have an A or B grade, under 
USPSTF or ACIP, and that do not have cost sharing.  He went on to ask how 
individuals not under the expansion would be treated.  Dr. Berman replied cost 
sharing does not address treatment.   Cost sharing is relevant for the individual 
plans.   Screening may be covered but treatment may not in some plans.   
Alternative plans are going to vary.  State plans do not have to be exact 
replications but do have to be equal in actuarial value.  Dr. Hewitt said cost 
sharing is part of the reality in some states and therefore empirically it will be a 
barrier to care.  There cannot be continuity of care if cost sharing is imposed on 
individuals who may not be able to pay.  Dr. Ho said programs might be able to 
broker with plans to overcome that barrier.  Dr. Hewitt proposed ACET examine 
the issue.  Dr. Dorman agreed and asked for Dr. Ho and her team’s guidance on 
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identifying ways for ACET to play a meaningful role on the matter.  Dr. Berman 
said there are many possibilities and shared responsibility may be the solution. 
 
Dr. Horsburgh asked how the HIV/AIDS quality measures get decided upon and 
put into the program.  He also reminded ACET that CDC did identify quality 
measures for TB and perhaps those should be revisited.   Dr. Berman did not see 
the Meaningful Use requirements as being the answer.  Only in Meaningful Use 3 
is there any look at performance.  Medicaid has new measures where they are 
interested in performance levels and that would be a good place to look.  The 
question is how to use quality community measures in an effective way, lobby for 
them, and then figure out ways to use those measures outside of the provider 
realm. Dr. Ho suggested foreign-born patients, who have been in the United 
States for awhile, as a possible group.  Those individuals tend to go to private 
providers and may offer a role for the QHPs.   
 
Dr. Narita felt public health should retain the responsibility of care for infectious 
TB cases, in order to protect the public.  Dr. Ho said it would be a local decision.  
She also suggested that ACET consider changing the term essential 
components, which may be confused with essential health benefits.   
 
Dr. Castro noted in the case of TB, states have public health laws and statutes in 
place to detain TB-positive individuals, if they have exhausted all means in 
getting them to seek treatment. However, he wondered how situations would be 
handled if a person were fiscally unstable and cannot afford care.  He suggested 
ACET consider those types of scenarios in its deliberations. 
 
Dr. Tompkins made ACET aware of the existing state of the health information 
exchange (HIE), which is not available currently.  Providers and health 
departments cannot communicate with one another’s systems causing silos and 
duplication of treatments and efforts.   Collaboration should be encouraged 
between local health departments, hospitals, providers, etc by opening access to 
one another’s systems to reduce duplication.  Dr. Ho said part of the 
requirements for Meaningful Use is having an IT structure that is be to able talk 
across systems.  Dr. Tompkins agreed with Dr. Ho, but she was referring to the 
actual implementation.  The capability is there for all systems that meet 
Meaningful Use, but the health information exchange still has not occurred.   Dr. 
Berman chimed in and said all HIEs are different in every place; therefore, the 
business models are different, and it is important that health departments can be 
part of the system.   
 
Going back to measurements, he also reminded ACET that no measurements 
would be given anywhere, if it were not National Quality Forum (NQF) endorsed.  
The only TB measure that is NQF-endorsed is testing among HIV positive 
patients.  There is no stand-alone measure for TB.  This is an area that needs to 
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Dr. Trump inquired, with Medicaid expansion, has there been discussion among 
programs of how to approach funding for TB control programs for states that 
don’t adopt Medicaid expansion and does it go under the funding formula for the 
TB program in the future.  Dr. Ho was not sure.  Dr. Trump said it should be 
considered.   
Dr. Doshi suggested ACET look to the Louisiana Public Health Information 
Exchange, for an example of HIE.  An alert has been implemented for HIV-
positive people that will help them to be linked back into care, if they have not 
been seen for some time by a physician.  There are also examples of where 
public health links to community providers.  With ACA, primary care doctors feel 
more burden is being put upon them, but the true expertise to handle TB are in 
the public health field.  DTBE needs to encourage more partnerships between 
physicians and public health.  She concluded by asking how does ACA work for 
incarcerated individuals.  Dr. Ho said they are not covered. 
 
Dr. Iademarco asked if the state has a public health law, does that trump what 
needs to be included under ACA.  Dr. Ho responded treatment of diseases is not 
stipulated by ACA, so treatment will continue to be handled by the states.   Dr. 
Iademarco then suggested the use of public health laws to address the gaps in 
fundamentals.  
 
Mr. Jones before adjourning the meeting for a lunch suggested ACET consider 
appointing a group to look at ACA over time and the impact it has on TB control 
efforts as well some of the other programs in the center, who also touch TB. 
 
The meeting was reconvened at 1:19 PM.  Dr. Dean took role and quorum was 
present.  Mr. Jones again reviewed the agenda. 
 
U.S. Preventive Services Task Force /Assessing Evidence for Treatment of 
LTBI as Prevention  
Dr. Christine Ho 
 
Dr. Ho’s second presentation was on the role of USPSTF in Latent TB Infection 
(LTBI) testing and treatment.  The healthcare reform requires coverage of certain 
preventive services.  These services pertain to individual and small group plans, 
Medicaid expansion plans, and must be offered without cost-sharing.  It covers 
all preventive services with an ‘A’ or ‘B’ grade recommendation from USPSTF, as 
well as the Advisory Council on Immunization Practices (ACIP) and Health 
Resources and Services Administration (HRSA)-supported recommendations.   
 
TB testing for children at high risk for TB is covered under ACIP and HRSA 
recommendations.  Moreover, USPSTF recommendations for LTBI screening of 
high risk person had an ‘A’ grade in 1996.  In 2002, USPSTF recommendations 
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The USPSTF is an independent group of national experts in prevention and 
evidence-based medicine.  The taskforce puts recommendations forward about 
clinical preventive services based on a unique systematic method.  The LTBI 
screening was declined by the USPSTF topic prioritization work group in past 
years because of duplication of efforts by federal agencies.  A joint-agency 
review was approved for this fiscal year, but budgetary impacts on funding have 
stalled the process.  The topic may not come up for review again and joint 
funding from AHRQ might not be available either; thus, the interagency 
agreement did go through last week.  A funding announcement will be coming 
this summer. 
 
The USPSTF assigns letter grades to signify the strength of each of its 
recommendations based on evidence supporting the benefits of the service.   
 A - strongly recommend 
 B - recommend 
 C - neither recommending for or against 
 D - recommending against 
 I - insufficient evidence to recommend for or against the service.  
 
The development of a topic recommendation takes 2-3 years, and 1-2 topics are 
selected each year.   Topics that meet criteria are prioritized according to public 
health importance and potential for a recommendation to affect clinical practice. 
 
There have been other communicable diseases that have gone through the 
taskforce review.  USPSTF uses the GRADE approach, which is an evidence-
based, systematic approach which places greater weight and emphasis on 
randomized control trials.  Public health studies frequently rely on observational 
cohort trial design.  The strength of the recommendation also depends on 
diagnostic tests, risks, and benefits of treatment.  Under the new USPSTF 
recommendations, HIV screening, for all ages 15-65, received a grade of A and 
hepatitis C screening, for the general population, a grade of D.   
 
The costs of treatment for services are not dictated by the USPSTF grade. 
Reimbursement of LTBI treatment and co-pay requirements are determined by 
each state’s alternative benchmark plan.  The HRSA-commissioned IOM 
reviewed preventative services and determined that they are necessary for 
women’s health and well-being and should be considered in the development of 
comprehensive guidelines for preventative services for women.  Dr. Ho pondered 
if there could be something similar for vulnerable populations or communicable 
diseases. 
 
The floor was opened for discussion. 
 
Dr. Makhene asked if cost sharing is only applicable when there is a Grade A.  
Dr. Ho responded preventative services that have an A or B grade are covered 
without cost sharing. 
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Dr. Horsburgh thought CDC was going to prepare the application but an FOA has 
been designated.  He asked if there are groups skilled at carrying out that 
process.  There are also other taskforces who are grading the same thing, so 
wondered could there be duplication.  Dr. Ho said the USPSTF study is 
completely separate and related to ACA.  CDC had to guarantee the systematic 
review was not duplicated by the current IDSA and ATS guideline workgroups or 
anywhere else.  CDC reached out to the LTBI Treatment Group, IDSA, and ATS 
to ensure that there was no overlap or duplicate services.  The original plan was 
for CDC to have more control over what questions were posed, but that has 
changed.   By having this jointly funded, CDC can sit in to make sure the review 
is going in the right direction but cannot influence the questions.  Therefore, Dr. 
Horsburgh concluded this would be a limited competition of those who have the 
skills.  Dr. Ho affirmed his assumption.  A set of research questions will be 
identified, and CDC can then share those questions with its partners. 
 
Ms. Cole wondered how the D rating against testing for hepatitis C related to 
screening the baby boomers born between 1945-1965.  There seemed to be a 
contradiction.  Dr. Ho agreed and the Hepatitis Division is currently working on 
the problem.  CDC’s recommendation is for a certain cohort born in those years, 
and the recommendation they were trying to attain was for the general 
population.  Dr. Berman said it is under consideration and not a final.  Hopefully 
by springtime more data will have been accumulated.   Dr. Ho added USPSTF 
would not re-review a topic unless there is new evidence. 
 
Dr. Narita wondered if LTBI screening methods can include both skin testing and 
interferon-Y release assay (IGRA) and whether the study to recommend should 
be based on each individual test.  Dr. Ho said it would have to be chosen through 
the evidence practice centers; although DTBE could suggest it.  Other new 
regiments could also be added to the list as well.   
 
Dr. Warkentin thanked DTBE for providing funding for the review in spite of the 
tough economic times.   
 
DRUG/DIAGNOSTIC SHORTAGES UPDATE 
   
Drug/Diagnostic Shortages - Field Perspective  
Dr. Jennifer Flood 
Chief, TB Control Branch, CDC 
President-Elect, National TB Controllers Association (NTCA) 
 
About two years ago, Dr. Flood gave a presentation to ACET with the same title 
and now wanted to update the committee on the current state of TB drug 
availability.  Some things have changed and some have remained the same.  
What have not changed are the essential components of the National TB 
Program.  ACET endorsed the recommendation to ensure that patients who have 
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TB receive appropriate treatment until they are cured and to treat patients without 
consideration of their ability to pay.  The International Standards says there 
should be an uninterrupted and sustained supply of anti-TB drugs.  Other 
components of the National TB Program include a reliable system of 
procurement and distribution of anti-TB drugs and that anti-TB drugs should be 
available free of charge both because patients are poor and may not be able to 
afford them and because treatment has benefits to society. 
 
Surveys show that 81% of U.S. programs report difficulties accessing second line 
drugs for MDR patients.  Ninety percent reported adverse outcomes, such as 
treatment delays, inadequate regimens, and treatment interruptions.  Shortages 
have occurred with eight anti-TB drugs to date.  Dr. Flood recounted a case of 
MDR TB in an infant and father.  Shortages of capreomycin and amikacin led to a 
delay in treatment initiation.  The infant, who had severe meningitis and 
hydrocephalus, was placed in serious danger. 
 
In addition, hundreds of drugs outside of TB have experienced some shortages.   
Included in that is INH and tubersol.    Between 2011 and 2013, in the U.S., 79% 
of individuals had difficulty obtaining INH.  Programs lost or turned away patients 
with indications for treatment.  TB contacts delayed access to INH and thousands 
of healthcare workers went without testing for months.   In addition, alternatives 
are not always palliative to institutions because of cost restraints.     
 
While there have been a number of acute shortages of INH and tubersol, others 
are reoccurring and chronic, and when medications were brought back into the 
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Interruptions in anti-TB medications 2011- 2013















Drug stock-outs are not an unfamiliar scenario.  About 18% of countries surveyed 
by the World Health Organization (WHO) reported interrupted supply of first-line 
drugs and 15% reported interruptions in supplies of second-line drugs.  The 
United States stands with the nations without a secure drug supply. 
 
Articles have been recently written on the issue.  Charity Thoman wrote an article 
about drug shortages.  The article was entitled U.S. Doctors Shouldn’t Have to 
Beg for TB Drugs, and was published on May 30, 2013. 
 
Large co-pays and the high price tag for many second and third line drugs are an 
issue.   There are escalating costs for first-line drugs and tuberculosis skin test 
(TST) solution -- rather a price gouging.  INH has increased 30 times its original 
price and Aplisol over 5 times over its original price during the tubersol shortage.    
 
There is a lot of hope for bedaquilline, a new drug, but it is very costly to public 
health because it requires an upfront purchase of the entire 6-month course.  
ACET needs to think of ways to overcome this barrier.   
 
Drug resistance has increased in the U.S., which raises concern.  Drug 
susceptibility trends, according to U.S. surveillance data, show increasing 
resistance to INH, pyrazinamide (PZA), and MDR treatments.  The questions the 
division needs to have addressed are: 
 
 
Advisory Council for the Elimination of Tuberculosis 
Centers for Disease Control and Prevention 
June 4 - 5, 2013   
26 
 What strategy will work to meet national program basic element of 
continuous drug supply; and  
 How will we get there?   
 
This issue is garnering more attention.  There have been some white papers 
created on the subject of drug shortages. In addition, at the Treatment Action 
Group Summit in Washington, D.C. 2013 the question was asked by C. Toman, 
“Can the model be one where patient/public safety becomes the paramount, 
most powerful driving force?” 
   
There are models to consider:  DHHS has the Vaccines for Children Program.  
There is also the Canadian TB Procurement and Supply and the Global Drug 
Facility.    Many lessons can be learned from these programs.  Moreover, 
leadership and experience can be garnered, from CDC and HHS, on vaccine 
supply programs, influenza drugs, and HIV drugs.  If can be done for those 
programs, it can be done for TB.  Dr. Flood said the focus of discussions should 
be on finding ways to prevent drug shortages versus just reacting to them.   
There needs to be a move to prevention, which requires a systematic strategy 
and prioritizing of public good.  The goal is not to return to past outcomes. 
 
The NTCA has developed a set of recommendations for CDC.  They are to 
support a continuous and affordable drug supply by: 
 Intensifying actions to prevent drug shortages 
 Establishing a dedicated team 
 Partnering with HHS, FDA, GDF and health departments 
 Building on existing models, like the vaccine program 
 Pursuing national procurement and distribution, and 
 Supporting needed regulatory changes 
 
Dr. Flood concluded by reminded ACET that several years ago it was not until 
several people died from fungal meningitis that the nation reacted.  It should not 
take the same before the nation becomes more proactive concerning TB. 
 
CDC Activities around Drug/Diagnostic Shortages  
Dr. Sundari Mase 
Medical Team Lead, Field Services and Evaluation Branch, DTBE, CDC 
 
Dr. Mase continued the drug shortage discussion.  Her presentation focused on 
the CDC strategies for securing adequate supplies for patients.  U.S. TB patients 
and TB programs have experienced recurring difficulty accessing first and 
second line TB drugs and are now also experiencing a Tuberculin Skin Test 
reagent shortage.  In addition to shortages, other barriers include climbing costs, 
multi-step processes for procurement, out-of-reach costs for uncovered patients, 
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Dr. Mase provided some background on shortages.  She re-reviewed information 
presented by Dr. Flood about the essential components of a National TB 
Program.  Access to uninterrupted, top quality, anti-TB drugs is DTBE’s priority.   
There have been barriers to treatment caused by several drugs from 2011-2013.  






 INH (isoniazid) 300 mg:  not currently available 
 Linezolid 





Shortages are contributed mainly to problems with manufacturing, which may 
include non-specific discoloration of product, glass shards, metal filings, fungal or 
other contaminants, especially an issue with injectable drugs.  Other reasons for 
shortage includes delays in manufacturing and/or shipping, active 
pharmaceutical ingredient (API) shortages, and increasing demand outpacing 
supply.  Challenges can also be attributed to issues outside of manufacturing, 
like passive surveillance/reporting, short-dated medications, single sources for 
some drugs, lengthy procurement process for certain drugs, manifestations of 
market forces, like hoarding, price increases and gouging, and market 
abandonment. 
 
The results of these shortages are delays in treatment or procedures and 
rationing or restriction of drugs.  There is also a need to use less effective 
alternative drugs, which have had the occurrences of medications errors and 
adverse events. Other consequences include increases in drug costs, increases 
in ancillary costs, more staff time dedicated to drug procurement, and labor costs 
for these activities.    
 
The impacts of shortages are also felt by patients, programs, and providers.  TB 
programs have lost credibility and cannot meet core functions.  There is the 
chance that TB disease manifestations may worsen.  Patients may acquire 
further drug resistance, and there could be increases in TB transmission.  The 
failed ability to respond to outbreaks will make for the perfect storm. 
 
CDC responded by actively tracking and reporting on other pharmaceutical 
shortages.  There have been six publications since December 2012 related to TB 
drug shortages.   State and local programs were altered in December 2012 to let 
them know the extent of the problem and to provide guidance.  A few months ago 
to assess the impact of the lack of INH, a survey was conducted.  More than 50% 
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of programs reported significant shortage of INH.  In mid-January 2013, CDC 
was notified that VersaPharm would not have INH until 2014.  CDC, FDA, and 
Teva worked together to provide an emergency allocation for state and local 
programs.  In addition, two national webinars on INH and Tubersol were 
presented.   
 
The Federal TB Taskforce Meeting was convened on Monday, April 8, 2013.  At 
the meeting, Dr. Chorba discussed current TB drug and pharmaceutical 
shortages.  Short and long term solutions were identified.   The short-term 
solutions included: 
 Establish a monitoring and early warning system 
o Use CDC’s Countermeasure Tracking Systems to track availability 
of pharmaceuticals and to respond to shortages in a timely manner 
 Formal designation of TB in the United States as a disease covered under  
the Orphan Drug Act 
 Establish regulatory requirements for early notification to FDA of potential 
shortages and of plans for product discontinuations  
 Offer financial incentives (e.g., tax credits) to drug makers to produce 
specific drugs in shortage 
 
Also identified were proactive, long-term solutions, such as  
 Create a national or regional TB drug repository 
 Accelerate review of requests for importation of quality assured drugs 
from the TB Global Drug Facility (GDF),  
 Form a strong regulatory and inspection network with other countries 
 Establish a qualified manufacturing partner program for drugs used for 
diseases that pose a public health threat, such as essential 
pharmaceutical list 
 
A week or two ago the division was asked to put together a white paper on stock-
outs.  Recommendations in the document were to create an early warning 
system for TB drug or pharmaceutical stock-outs.  The document also spoke to a 
centralization distribution of TB drugs, by identifying distributors to maintain a 
certain level of TB drugs and obtain drugs from foreign manufacturers, when 
unavailable in the United States.  It also addressed improving timeliness of 
reporting of drug shortages by drug suppliers.  
 
This issue is not going to go away and will require further discussion.  
Participation of CDC, FDA, and other federal agencies in addressing this issue is 
paramount.  DTBE in its capacity of overseeing the National TB Program's 
prevention and control activities needs to consider undertaking a new role, and 
the division welcomed ACET’s recommendations on how to move forward. 
 
Dr. Mase concluded the presentation by providing the FDA website address 
regarding drug shortages as well as its email address designated to this issue: 
  http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050792 
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 drugshortages@fda.hhs.gov  
 
An Update of the Diagnostics Work Group of the Federal TB Task Force  
Dr. Michael Iademarco 
Captain, U.S. Public Health Service  
Chief, Laboratory Branch 
 
Dr. Iademarco provided a brief update from the Diagnostic Work Group of the 
Federal TB Taskforce.  The taskforce is comprised of individuals from CDC, 
FDA, and the National Institute of Allergy and Infectious Disease (NIAID).   The 
update was focused on diagnostic laboratories, which was also highlighted in the 
February 13, 2009 edition of the MMWR.   
 
The first issue presented was the diagnostic delays, for NAA tests.  The delay 
was a significant factor in 27 CDC-investigated outbreaks between 2002–2008.  
In 2009, public health laboratories (PHLs) performed NAA testing for M. 
tuberculosis for 14% of TB suspects.  Cautious guidelines were released in 1996 
and 2000 due to the limited evidence of programmatic effectiveness, and in 
2009, CDD updated the NAA testing guidelines.  The January 16, 2009 MMWR 
said, “NAA testing should be performed on at least one respiratory specimen 
from each patient with signs and symptoms of pulmonary TB for whom a 
diagnosis of TB is being considered but has not yet been established, and for 
whom the test result would alter case management or TB control activities.” 
 
Issues with NAA are not the only reason for delays, in TB testing.  It has been 
estimated that 28% of patients with negative sputum smears and positive sputum 
cultures are not started on treatment until culture results are available.  A liquid 
culture for M. tuberculosis can take weeks to grow.  In addition, it has been found 
that 72% of PHLs meet benchmark of identifying M. tuberculosis within 21 days 
of specimen receipt. All of this underscores the need for rapid and accurate 
testing for TB diagnosis, especially if the acid-fast bacilli (AFB) smear shows 
negative.  Currently, there are no FDA-approved molecular tests to detect drug 
resistance. 
 
Within the last few years, two conferences have helped to build momentum 
around these matters.  In June 2010, The Advancing the Development of 
Diagnostic Tests and Biomarkers for Tuberculosis meeting was held, and a year 
after, in June 2011, a workshop on TB and HIV Diagnostics in Adult and Pediatric 
Populations was convened.   
 
The Diagnostic Work Group, at its last meeting, reviewed progress made since 
2011.  Several activities have occurred.  There was the establishment of the FDA 
and NIH co-sponsored clinical trial specimen bank to aid in biomarker discovery.  
Also occurring was a joint activity between CDC and NIH on improving diagnostic 
testing for pyrazinamide resistance.  CDC and NIH also coordinated with WHO 
for moving research and development to field demonstration for molecular 
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detection of drug resistance.  Meanwhile, the FDA has worked on policy efforts 
for devices that detect M. tuberculosis and related drug resistance.  CDC, the 
Tuberculosis Trials Consortium (TBTC), NIH, and the AIDS Clinical Trials Group 
(ACTG) collaborated on a U.S. Expert study to contribute to FDA registration, 
and another major step was the Diagnostics Research Forum, which was a 
collaboration between NIH, the Bill and Melinda Gates Foundation (BMGF), and 
CDC. 
 
As a result of the work groups analysis, there have been three meetings related 
to PZA and poor drug susceptibility testing. 
 May 2011, NIH, Essentiality of PZA 
o Outcome:  “PZA has potent sterilizing activity and is a highly 
important drug in current anti-tuberculosis combination therapy. 
Unfortunately, while PZA-resistant TB has been increasing 
worldwide, rapid and reliable diagnostic tools for the detection of 
PZA-resistant TB are still unavailable. This presents a major barrier 
for treatment, especially for multidrug-resistant and extensively 
drug-resistant disease. PZA is the least understood anti-TB drug 
due to its complex mechanisms of action and obstacles in 
establishing animal models for PZA testing Hafner.”  
 December 2011, CDC PZA Day 
o Outcome:  CDC presented information on the surveillance of PZA 
resistance, experience in providing clinical microbiologic service, 
and preliminary results on approaches to improve drug 
susceptibility testing for PZA. A series of concrete actions steps 
were laid out for the various federal agencies to strengthen internal 
U.S. government interaction.  
 September 2012, NIH “Demystifying PZA—Challenges and Opportunities”  
o Outcome:  “Topics included mechanisms of action; drug resistance 
and associated testing; combination therapy; and toxicity. This 
meeting was the pre-step to the announcement of a NIH-sponsored 
“TB Diagnostics Research Forum”  
 
After the September 2012 meeting, the work group identified a set of next steps.  
One is to understand molecular markers of resistance for fluoroquinolone (FQ) 
and other important drugs.  Other steps include pediatric TB diagnostics, 
standardization of laboratory processes for clinical trials, improved platforms for 
rapid resistance testing beyond rifampin, and MDDR for surveillance 
internationally. 
 
The floor was opened for questions.   
   
Ms. Bur expressed concern over issues with NAA, from correctional facilities, 
being refused by state labs.  According to Dr. Iademarco, the taskforce works 
with lab directors, in the states, to answer questions and provide technical 
assistance.   A more detailed dialogue is needed to clarify and dissect the matter, 
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in order to identify easy wins and low-hanging fruits.   Dr. Elson suggested 
preparing guidance, in general, for the detention systems, as opposed to just 
facilities, which will help with transient issues and duplicative testing.   
 
Dr. Dorman wondered if there was anything, further that ACET could do.  She 
was not sure if this was the time for ACET to be reengaged with resolutions.  Dr. 
Castro felt there was a benefit from ACET endorsement, which encourages 
DTBE to move ahead.  However, DTBE will not wait for ACET before it takes 
action.  It will use every tactic available to ensure success. 
 
Drs. Flood and Mase have put forward recommendations.  They asked if ACET 
uncovers any gaps to please notify them.    
 
Dr. Horsburgh said CDC should take the lead in this.  He would want to set up 
something new and felt existing mechanism should be employed.  Dr. Baine 
suggested the use of a mechanism that was more radical related to national 
products.  The government, he felt, should acquire manufacturing capabilities.  
Dr. Flood was in agreement; however, Dr. Mase felt existing mechanisms should 
be examined.  Dr. Baine replied that public health would be “crazy” to think it was 
someone else’s responsibility to fund drug manufacturing.  Dr. Reichman added 
TB’s history is replete with incidences of slow response.   If there are new 
technologies, they should be utilized.  Dr. Flood said the biggest barrier is 
money, even if you have alternatives.  
 
After the break, roll was taken and quorum was present.  Mr. Jones, again, 
reviewed the agenda 
 
Ms. Suzanne Marks read, for the record an addendum for Task Order 27, which 
was made available online, as of May 22.  It read as follows: 
 
The Health-System Benefits and Cost-effectiveness of using M. Tuberculosis 
Direct NAA Testing to Diagnosis Tuberculosis Disease in the United States.   
 
Potential Audience: Tuberculosis and infectious disease clinicians and health 
economists.   
 
Key Message:  The M. tuberculosis Direct (MTD) NAA test improved diagnostic 
accuracy and timeliness, and reduced unnecessary respiratory isolation, 
treatment, and contact investigation.  It was cost savings in patients with HIV, 
recent homelessness, or substance abuse, but in others. 
 
Talking Points: 
1. Improvements in diagnosis of TB disease are needed, since sputum-
smear microscopy detects less than half of TB patients. 
2. For patients suspected of having pulmonary TB, the CDC has 
recommended since 1996 that nucleic acid amplification testing be 
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conducted on at least one respiratory specimen if sputum-smear positive, 
and since 2009 if sputum-smear negative. 
3. The U.S. Food and Drug Administration approved an enhanced MTD in 
1999 for both smear-positive and smear-negative specimens. 
4. Individual providers, hospitals, and laboratories determine its use.  
However, the nucleic acid amplification testing is not used universally. 
5. Data on its programmatic benefits and cost-effectiveness might influence 
its use. 
6. The study evaluates the use, effectiveness, health system benefits, and 
cost-effectiveness of MTD nucleic acid amplification testing from the 
largest known cohort of patients suspected of pulmonary TB reported in 
2008-2010 from multiple U.S. sites. 
7. Compared with no MTB, we found: 
a. Improved diagnostic accuracy for all patients 
b. Reduced time to TB diagnosis in smear-positive/MTD(+) 
c. Reductions in medical procedures and respiratory isolation for 
smear-positive/MTD(-) patients without TB 
d. 1.5 fewer months of unnecessary and potentially toxic TB 
medications in MDT(-) patients without TB 
e. Fewer contact investigations initiated for smear-positive/MTD(-) 
patients without TB 
f. Cost savings per additional patient with HIV or homelessness 
diagnosed without TB or excluded with TB, and per smear-negative 
patient with substance abuse to exclude TB 
8. Study results provide a baseline for newer molecular TB disease 
diagnostics, such as Xpert. 
   
Task Order 18 Update and Recommendations  
Dr. Wendy Thanassi 
National Lead, Tuberculosis, Veterans Health Administration Office of Public 
Health, Occupational Health Strategic Healthcare Group,  
Chief, Occupational Health, VA Palo Alto Healthcare System 
Assistant Clinical Professor, Emergency Medicine, Stanford Medical Center 
 
Dr. Thanassi presented results and reversions from work completed by the 
Interferon Gamma Release Assay (IGRA) Sounding Board.  The board also 
presented a set of resolutions to be considered.  [See Day 2, Resolutions 
section.] 
 
IGRAs have several uses in practice.  Both the 2010 CDC and the 2008 
American College of Occupational and Environmental Medicine (ACOEM) 
guidelines support IGRA use as an alternative to TST in serial testing.  The 
adoption of IGRA is growing, principally in healthcare worker (HCW) screening 
programs.  The IGRAs offer both advantages and challenges in serial testing.  
The management of variability around the dichotomous cut-point poses 
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significant challenge, but multiple protocols are emerging to prevent over-
treatment based on transiently positive results. 
 
There is a lot of talk of reversions in the literature with regard to IGRAs.  One, in 
particular, appeared in the CHEST December 2012 issue.  It stated, “It is now 
clear that a simplistic definition of conversion (i.e. change from negative to 
positive) is no longer acceptable from a programmatic perspective. Additionally, 
given the high rates of reversions, it may be necessary to routinely repeat the 
IGRA in a recent convertor before decisions are made about preventive therapy. 
Until future iterations of guidelines address these issues, occupational health 
programs must … not rely on dichotomous (yes/no) results...”  But there were no 
guidelines for next steps.  Therefore, in June 2012, the IGRA Sounding Board 
produced a set of objectives to “[address} variability around the cut-point in serial 
IGRA testing.”  During the meeting, the board heard presentations regarding the 
high number of positive results and reversions observed in serial testing.  They 
also discussed testing algorithms.  Consensus of opinion helps to guide 
programs using IGRAs in serial testing, and the board is considering national 
guidance on IGRAs. 
 
The board is co-chaired by Dr. Kenneth Castro and Dr. Charles Daley.  
Participants on the board are from organizations, like CDC, the TB Epidemiologic 
Studies Consortium (TBESC) Taskforce, ACOEM, APHL, and tuberculosis 
experts with research findings or extensive experience using IGRAs. 
 
Dr. Thanassi presented two study designs that were presented at the board’s 
meeting.  The first was the TBESC Study Design - Task Order 18, which was a 
multi-center longitudinal study of serial testing in HCWS comparing IGRAs and 
TST.  The study was performed in South Central, Rocky Mountain, Mid-Atlantic, 
and New England, among 2,500 HCW participants.  It examined QuantiFERON-
TB test (QFT), TSPOT and TST over 0, 6, 12 and 18 month durations.  The study 
found that compared with TST, baseline testing with an IGRA reduces LTBI 
diagnoses by 80% among BCG-vaccinated.  This ultimately showed cost savings 
and incremental benefits.  It also demonstrated that prior TST could boost IGRA 
results, mostly in the TST positive.  The effects last approximately 6 months.  
Positive result percentage was similar on all three tests, but with poor agreement.  
The following result percentages were seen: 
 5.2%  TST 
 4.9%  QFT 
 6.0%  TSPOT 
          1.4% positive by all three tests 
 
This begs the question of why there is such poor agreement.  These numbers 
were just over the cut point.   
 
Ultimately, the TBESC Task Order 18 exhibited conversions and reversions 
occurred with all 3 tests, but significantly more often with IGRAs.   
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   Conversion rates: TSPOT     8.3 % 
      QFT        6.1 % 
      TST       1.0 % 
 
Most IGRA conversions do not represent true change in infection status.  
Conversions with IGRAs occurred most frequently with quantitative results that 
were close to the cut-point, and almost 75% of IGRA conversions were transient.  
Therefore, strategies for discerning “true” IGRA conversions are needed.  Until 
then, caution should be used in interpreting a single, newly positive test in a low-
risk HCW. 
 
The second study was called the Palo Alto Model – A Retest Zone, which was a 
multi-center statistical analysis to predict QFT reversions versus consistently 
positive result.  The study was conducted in VA Palo Alto Health Care System 
(VAHCS), University of Illinois at Chicago (UIC), and the Cleveland Clinic.  The 
method used to analyze was the Receiver Operating Characteristic analysis, 
which is a statistical method that differentiates similar appearing groups based on 
attributes.  Participants were as follows: 
  862 serially tested HCWs with positive QFT 
  29,000 tests, 14,000 HCWs, 9.6% positive,     
   52% reversions 
 




TST vs. IGRA Testing
n = 28,828 QFTs
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Reversions at <1.11 IU/ml, p<0.001 





The result was a reversion rate of 76%.  Retesting can be done as soon as the 
next day. The board’s data was presented to Dr. Castro and was published in 
Pulmonary Medicine’s December 2012 issue.   
 
The Palo Alto Model is the largest study of IGRA positive U.S. HCWs to date 
representing HCWs across the U.S.  The retesting zone consistent with 3 sites 
and with 7 sites validates CDC recommendation for quantitative reporting, 
algorithms that are currently improvised (OH), and ideal retesting zone at <1.1 
IU/ml.  Therefore, this should be a considered regiment.  Additional analysis can 
add to future algorithms. 
 
At the conclusion of the board one year ago, it was determined that IGRA testing 
of low risk persons causes transient, low-positive results that may not represent 
infection.  A retesting strategy for low risk HCWs is needed to clarify QFT 
conversion.   The board also established that “there was unanimous consensus 
that national guidance, led by the CDC, is needed to formulate an optimal 
strategy or set of systematic approaches to address the unexpected high rates of 
positive IGRA results in the serial testing of low risk persons.“  This guidance was 
felt to be urgent because providers and laboratories are faced with the issues of 
conversions and reversions on a daily basis.  The summary of the June 2012 
meeting was published in the Infection Control and Hospital Epidemiology, 
Volume 34, No.6 (June 213), pp. 623-630. 
 
Dr. Thanassi asked ACET to consider the following: 
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 Serial testing of low-risk adults in a low-prevalence setting leads to high 
levels of reversion, with 77% of those testing between 0.35 and 1.1 IU/ml 
reverting on retest. 
 Identification of a QDT retesting zone prevents misdiagnosis and 
treatment of LTBI without compromising sensitivity. 
 
Therefore, CDC guidance in interpreting quantitative IGRA results in low-risk 
adults is requested, particularly recommendation for a QFT IGRA retesting zone 
in the low-risk adult. 
 
 Establishment of a working group to identify algorithms for testing and 
treating based on quantitative IGRA results,  
 Recommendation that quantitative IGRA interpretation be included in the 
next revision of the MMWR. 
 
The floor was opened for questions.   
 
Dr. Ekiek queried if island nations should utilize the recommendations, since they 
are experiencing difficulty accessing tubersol.  Dr. Thanassi suggested the use of 
IGRA, which will relieve the burden of possibly exposing false-positive 
individuals.  She suggested that Dr. Ekiek speak with Ms. Eva Margolies on the 
matter. 
 
Dr. Baine asked about the effects of IGRAs on vitamin D levels.  She replied the 
issue has been taken into consideration, when the analysis is performed on 
individuals who revert.   If there was a vitamin D influence, it was quite small.   
 
Dr. Narita felt the data underscores the need to revise the guideline.    
 
Dr. Burgos asked for an update on T-spot, since it has different measurements.  
Dr. Thanassi said the test has built into it a borderline zone.  The European cutoff 
is dichotomous to the board’s number of six.   The reversions with T-spot were 
higher compared to IGRAs.  The data should be examined carefully.  Dr. 
Horsburgh wondered if Dr. Dorman’s group could quantify the results with 
another test.  Dr. Thanassi said the issue has been addressed with statisticians; 
however, since this is not a probability issue, the results would be valid and 
independent.   This would be a different draw on a different day. Their interferon 
gamma may be different between those two days.  Drs. Thanassi and Horsburgh 
agreed to talk more offline about testing.   
 
Dr. Seaworth said ACET’s recommendations should specify IGRA for low risk 
individuals only.   Healthcare workers, she said, are not the only people who 
have reversions.  Dr. Thanassi would defer to ACET for a definition of low risk.   
 
Dr. Trump suggested ACET also look at the guidance in partnership with OSHA 
and determine if they should be doing all the testing for low risk individuals.   
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TB Corrections Update  
Ms. Sarah Bur, Ms. Diana Fortune and Ms. Lauren Lambert gave a combined 
presentation on corrections.  Dr. Jane Carter’s portion of the presentation 
displayed three TB case studies. The case studies exemplified what could go 
wrong in corrections. 
 
Case study one was related to drug-resistant TB mismanagement.  An 
Immigration and Customs Enforcement (ICE) detainee, who tested positive for M. 
tuberculosis on a culture, was placed in a detention center, on November 2012.  
The inmate was started on a regiment of rifampin, isoniazid, pyrazinamide, and 
ethambutol (RIPE) and moved to a local detention center in Texas.  After two 
months, PZA and ethambutol were discontinued.  The inmate then entered a 
federal bureau of prisons (BOP) facility in March of 2013.  It was determined that 
the culture obtained at the ICE was INH-resistant.  The inmate is now at risk for 
cultivated MDR TB.  A follow-up on this case study showed that there might be 
hope for this individual.  GeneExpert did show sensitivity to rifampin. 
 
The second study presented was a case of diagnostic delay.  An individual was 
detained at a local Texas detention center, in October 2012, who was 
symptomatic at intake.  The detainee tested TST negative, but in December 2012 
showed an abnormal chest radiograph that was said to have pneumonia.  The 
individual was moved to another detention center in February 2012 still 
symptomatic (coughing) and was shortly thereafter moved to a BOP facility in 
March.  An AFB smear, as well as an NAAT, reflected a positive result for M. 
tuberculosis.  As a result, a contact investigation had to be conducted at three 
facilities.  The preliminary results at the BOP documented 6/25, 24% TST 
conversions.  There is no data as of yet from the other two facilities.    
 
The final case also related to diagnostic delays.  A 26-year old female was in 
custody at a private Arizona prison in October 2012.  The female also briefly 
stayed at a Nevada correctional facility, where it was reported she coughed 
relentlessly but was not examined.  She was then placed in a BOP on March 15, 
2013, resided there until May 10, and was never examined for the cough, which 
continued.  In was not until an interview was conducted that it was discovered 
that the persistent coughing had started in October 2012.  On May 10, a chest 
radiograph showed bilateral disease with cavitations.  There have been 47-
documented TST converters.  Below are the percentages presented:   
 18% conversion rate on housing unit 
 >10% conversion rate on adjacent housing unit  
 >10% conversion rate at work site 
 
An investigation is now underway, in Arizona and Nevada. 
 
Ms. Diana Fortune did second part of the presentation, which was an update on 
the National Tuberculosis Controllers Association/National Tuberculosis Nurse 
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Coalition (NTNC) Corrections Committee.  The committee’s mission is to improve 
TB recognition, prevention, and control in correctional facilities.  The committee 
has designed its work plan for 2012/2013, and it can be found on the NTCA 
website, at http://www.tbcontrollers.org/ntca-2/committees/corrections/#.Uau_oJxnerg.   
 
The committee is made up of 48 members from the following agencies: 





 U.S. Marshalls 
 Local Correctional Facilities 
 TB Net 
 CURE TB 
 
They are hoping to increase the number of correctional agencies, particularly 
individuals with management responsibilities. 
 
The committee has formed three Work Groups to help it accomplish its mission: 
Surveillance for Action, Education and Training, and TB Liaison.  The work 
groups are chaired by Carla Chee (AZ), Ann Sittig (MN) and Barbara Vassell 
(TX), and Ellen Murray (SE National TB Center) respectively. 
 
The purpose of the surveillance group is to enhance surveillance reporting 
among TB cases in correctional facilities and to use data for public health 
decision making and actions toward the ultimate goal of eliminating TB.   To date, 
the work group has accomplished the following: 
 The DTBE Surveillance Team completed a slide set for 1993–2011 
Corrections data.  The NTCA work group assisted in review of slides. 
o Posted to NTCA website 
o E-mailed to State TB Correctional Liaisons 
 The work group developed a draft recommendation to clarify the RVCT 
correctional facility variable in the CDC instructional manual.  
 The work group requested an analysis from the CDC to review national 
reporting completeness of the correctional facility variable.  
 
The Education and Training Work Group’s mission is assuring that targeted 
education regarding TB and corrections are available for health departments and 
correctional partners.   They are currently developing a central repository of 
educational tools and ensuring that they are accessible to public health and 
correctional partners.  The desire is to vet current materials, determine gaps for 
future educational tool development, and develop domain name to increase 
recognition and awareness.  They also will promote collaboration between public 
health and corrections by presenting at educational conference on a national, 
state, and local level.  The following individuals will present: 
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 Phil Griffin  (KS) 
 Barbarah Brissett (Houston) 
 Sarah Bur  (BOP) 
 Ellen Murray (SE NTC) 
 
Lastly, the Corrections TB Liaison Work Group’s objectives are to expand the 
awareness of the challenges of TB in correctional facilities through collaborative 
efforts with the larger corrections committees and develop corrections liaisons for 
resources and link with experts in all aspects of corrections.  The work group’s 
accomplishments include a listing of all Correctional Liaisons for the United 
States and its territories.  The list is posted on the NTCA website.  It has been 
utilized to send out notice of INH and Tubersol shortages, in Jan 2013 and to 
send TB Correctional Surveillance slide set, in May 2013.  The work group has 
also performed a needs assessment questionnaire of the TB Correctional 
Liaisons and in conjunction with the RTMCCs are developing an on-line TB 
correctional liaison training.   
 
The committee will have an abstract/poster of its accomplishments showcased at 
the corrections annual meeting, on Wednesday, from 12:45 PM to 2:00 PM.  New 
members are always welcomed to join.  There will also be a breakout session, at 
the annual meeting on Wednesday, at 3:45 PM.  The goal of the breakout is to  
examine a variety of strategies and models of collaborations between public 
health and correctional partners and to discuss incorporating IGRAs into the 
correctional setting. 
 
The final portion of the presentation was presented by Ms. Lauren Lambert, who 
gave an update on the DTBE Corrections Work group.  The mission of the work 
group is to enhance the prevention, control, and treatment of LTBI and TB 
associated with correctional facilities.  The work group has performed activities in 
response to the eight resolutions, for correctional facilities, put forward by ACET, 
which relate to coordination, correctional liaison defined in TB CoAG, 
surveillance, TB case detection, continuity of care, education, treatment of LTBI, 
and Funding. 
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 Strengthen the coordination and 
oversight of TB prevention and control in 
correctional and detention facilities in 
partnership with state TB programs. 
 
 Conduct a formal evaluation to assess the 
need for a full-time staff person to 
coordinate these activities.   
 
 Develop ongoing collaborative 
partnership with national and regional 
correctional organizations to advance TB 
















Correctional Liaison Defined in TB CoAG 
DTBE incorporate into the new 2015 TB 
Cooperative Agreement the following proposed 
language:  
Status 
 “TB prevention and control in 
correctional and detention facilities is a 
high national priority.   
 
 Each Cooperative Agreement recipient 
will designate a correctional liaison and 
provide a brief summary report of 
activities in the interim and final progress 
reports.    
 
 Each jurisdiction should determine local 
priorities for the TB correctional liaison 
utilizing the NTCA Public Health TB 
Corrections liaison model duty statement as 





 Develop a plan for using TB surveillance 
data as a programmatic tool to identify 
burden of disease in correctional settings 
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studies.  
 Publish a brief annual summary of trends 
in TB in correctional and detention 
facilities that is made widely available and 
promoted for use by state TB programs to 
make data driven decisions about resource 
allocation.  
Partially-initiated 
 Add a question to the Report of Verified 
Case of Tuberculosis the next time it is 
updated:   “History of incarceration in the 
last (one or) two years.” 
Not initiated but 
on the agenda.  




TB Case Detection 
DTBE Status 
 Identify methods to improve TB 
screening, case detection, and medical 
management of persons with suspected TB. 
Partially-initiated 
 Emphasize the appropriate use of rapid 
testing in the diagnostic evaluation of 
persons in the legal custody of a law 
enforcement agency.   
Partially-initiated 
 Develop algorithms for returning inmates 




states have been 
able to develop 
algorithms. 
Continuity of Care 
DTBE Status 
 Conduct state specific analyses of the low 
rates of TB treatment completion among 
persons incarcerated at diagnosis and work 
with state and local health departments to plan 
to improve completion rates.   
Partially-
initiated 
 Evaluate the effectiveness of CURE-TB and 
TB-NET for transnational referrals and explore 
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 Explore the possibility of establishing a 
central system to obtain completion of 
treatment information from foreign 
countries for patients who have moved or 
been repatriated outside the U.S. 
Not initiated  
  Identify successful programs for 
improving continuity of care and TB 
treatment completion for TB cases 
identified in correctional facilities and 





DTBE instruct the RTMCCs and the appropriate 
DTBE branches to coordinate strategies to 
identify and meet TB learning needs of 
correctional administrators, correctional health care 
providers , infection control personnel, law 
enforcement/correctional officers, and inmates.  
Status 
 Conduct a needs assessment. Not initiated  




 Develop TB competency assessment tools 
for correctional health care providers. 
Partially-
initiated 
 Collaborate with correctional partners to 
identify methods to assure that 
correctional health care providers and 
infection control staff receive TB education 
and that there is a means to demonstrate TB 
competency.   
Partially-
initiated 
Treatment of LTBI 
DTBE Status 
Identify ways to expand treatment of latent TB 
infection in correctional facilities (including 






Advisory Council for the Elimination of Tuberculosis 
Centers for Disease Control and Prevention 
June 4 - 5, 2013   
44 
DTBE Status 
 Partner with key stakeholders to leverage 
existing and future resources for TB 
prevention and control in correctional and 
detention facilities (e.g., funding and 
resources from Program Collaboration and 
Services Integration activities,  emergency 
preparedness programs, HIV/viral 
hepatitis/diabetes-related organizations, 
programs working with immigrant populations, 




Ms. Lambert concluded by providing a snapshot of CDC accomplishments.  The 
DTBE Corrections Work Group has been established and surveillance 
corrections slide set posted.  “Predictors of failure in timely TB treatment 
completion” was published in the International Journal of Tuberculosis and Lung 
Disease, 2012 Edition.  Educational materials and training for Corrections 
Liaisons are being created and Molecular Epidemiology Activity is developing 
methods to identify corrections-related TB clusters.  There have been posters 
and presentations given at conferences and meetings about TB in corrections.  
She concluded her presentation by emphasizing that TB in Corrections is a 
priority for DTBE. 
 
The floor was opened for questions.   
 
Mr. Jones thanked DTBE for the work they have moved on in regards to ACET’s 
recommendations.  The board had no questions related to the presentation.   
 
The board moved to working on two proposed resolution.  The first was 
presented by Dr. Dorman.  It was developed in partnership with the TB Action 
Group and read as follows: 
 
Recommendation to revise proposed DTBE FY 2014 budget 
allocations in response to sequestration-mandated reductions 
 
The members of the Advisory Council for the Elimination of 
Tuberculosis (ACET),  
 
Determined to eliminate tuberculosis (TB) in the United States; 
 
Conscious of fiscal constraints and the need to allocate limited 
resources wisely in a period of nascent economic recovery;    
 
Voicing the concern of TB patients, healthcare providers and TB-
affected communities regarding the long duration and serious 
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toxicities of current therapeutic regimens and the urgent need to 
develop shorter, more efficacious, and better-tolerated therapies;  
  
Seriously concerned that proposed budget allocations to the 
Centers for Disease Control and Prevention (CDC) Department of 
Tuberculosis Elimination (DTBE) under federally mandated 
sequestration will delay these necessary scientific and clinical 
advances;   
 
Alarmed especially that the proposed budget allocation will severely 
curtail meaningful research in this area carried out by the 
Tuberculosis Trials Consortium (TBTC), the world’s premier TB 
research consortium that has been 19 years in the making, as well 
as the Tuberculosis Epidemiologic Studies Consortium (TBESC);  
 
Recalling that Public Health Law No. 110.392 encourages the 
Secretary of Health to “give priority to programmatically relevant 
research so that new tools can be utilized in public health practice;”  
 
Further recalling that that Public Health Law encourages the 
Secretary of Health to carry out, directly or through grants, 
“research and development and related activities to develop new 
tools for the elimination of TB, including drugs, diagnostics, 
vaccines and public health interventions;”  
 
Recognizing that programmatic relevance and public health impact 
sit at the heart of the TBTC’s scientific missions, as well as that of 
the TBESC;  
 
Recognizing also the strong programmatic value of TBTC and 
TBESC research, which has led to the recent development of a 3 
month regimen for LTBI treatment and ongoing efforts to develop a 
4 month treatment regimen for TB disease, advances which will 
increase the acceptability and cost-effectiveness of TB treatment 
and can be expected to contribute materially to our ability to 
eliminate TB in the US;  
 
Have agreed, as follows:   
 
For the fiscal year 2014 budget, we encourage the Secretary to 
preserve the research component of the DTBE.  
 
Dr. Dorman put the resolution forward and a motion for ACET consideration.  The 
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Ms. Jervis alerted the committee to Treatment Action Group’s recent advocacy 
work related to the 13% reduction in budget to CDC.  A series of meetings have 
begun, as well as usage of social media to bring about attention to the matter.  
She encouraged ACET to approve the resolution.  . 
 
Dr. Narita asked the committee if the item proposed on the resolution is the one 
item the committee wants to emphasize and if ACET is intending to suggest a 
shift of priorities.  Dr. Horsburgh agreed.  The idea is not to pit on side of TB 
against the other.  The intent is to preserve the research function.  The language 
should encourage the Secretary of Health to restore the 2013 cuts to the 
research components and preserve it in the future.  The committee edited the 
document to Drs. Narita and Horsburgh’s suggestions. 
 
Drs. Roselle and Brenner suggested an annex page with a list of the 
accomplishments be added, for the purpose of Congress.  After some 
grammatical edits, the following resolution was reread into the record, as a 
motion:  
 
Recommendation to revise proposed DTBE FY 2014 budget 
allocations in response to sequestration-mandated reductions 
 
The members of the Advisory Council for the Elimination of 
Tuberculosis (ACET),  
 
Determined to eliminate tuberculosis (TB) in the United States; 
 
Conscious of fiscal constraints and the need to allocate limited 
resources wisely in a period of nascent economic recovery;    
 
Voicing the concern of TB patients, healthcare providers and TB-
affected communities regarding the long duration and serious 
toxicities of current therapeutic regimens and the urgent need to 
develop shorter, more efficacious, and better-tolerated therapies;  
  
Seriously concerned that proposed budget allocations to the 
Centers for Disease Control and Prevention (CDC) Department of 
Tuberculosis Elimination (DTBE) under federally mandated 
sequestration will delay these necessary scientific and clinical 
advances;   
 
Alarmed especially that the proposed budget allocation will severely 
curtail meaningful research in this area as carried out by the 
Tuberculosis Trials Consortium (TBTC), the world’s premier TB 
research consortium, and the Tuberculosis Epidemiologic Studies 
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Recalling that Public Health Law No. 110.392 “Comprehensive 
Tuberculosis Elimination Act” Section 317E No. 2 encourages the 
Secretary of Health and Human Services to “give priority to 
programmatically relevant research so that new tools can be 
utilized in public health practice;”  
 
Further recalling that Public Health Law No. 110.392 encourages 
the Secretary of Health and Human Services to carry out, directly or 
through grants, “research and development and related activities to 
develop new tools for the elimination of tuberculosis, including 
drugs, diagnostics, vaccines and public health interventions;”  
 
Recognizing that programmatic relevance and public health impact 
sit at the heart of the scientific missions of the TBTC and TBESC;  
 
Recognizing also the strong programmatic value of TBTC and 
TBESC research, which has led to the recent development of a 3 
month regimen for LTBI treatment and ongoing efforts to develop a 
4 month treatment regimen for TB disease, advances which will 
increase the acceptability and cost-effectiveness of TB treatment 
and can be expected to contribute materially to our ability to 
eliminate TB in the US;  
 
Have agreed, as follows:   
 
For the fiscal year 2014 budget, we encourage the Secretary of 
Health and Human Services to rescind the FY2013 cuts and 
preserve the research component of the DTBE.  
 
The motion was seconded by Dr. Horsburgh.  Mr. Jones called for a vote.  The 
committee voted to unanimously accept the resolution. 
 
WRAP-UP DISCUSSION  
Shannon Jones 
 
Mr. Jones concluded the meeting with instructions for submitting the remaining 
resolutions for Day Two.  After some brief housekeeping notes, the meeting was 
adjourned. 
MEETING ADJOURNED  
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WEDNESDAY, JUNE 5, 2013 
CALL TO ORDER  
Mr. Shannon Jones called Day Two’s meeting to order at 8:31 AM.  Dr. Hazel 
Dean conducted the roll call and quorum was present.  After briefly reviewing the 
day’s agenda, the meeting promptly began with presentations. 
TB IN THE HOMELESS 
HRSA Perspectives on the Homeless  
Dr. Seiji Hayashi 
Chief Medical Officer, Bureau of Primary Health Care, HHS 
The mission of the Bureau of Primary Health Care (BPHC) is to improve the 
health of the Nation’s underserved communities and vulnerable populations by 
assuring access to comprehensive, culturally competent, quality primary health 
care services.   The Health Center Program was authorized under section 330 of 
the Public Health Service (PHS) Act.   
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Federal support for health centers began in 1965.   The grant programs 
established were for not-for-profit private or public entities, in all states and 
territories.  The Federally Qualified Health Center (FQHC) established under the 
program was through CMS designation.  Dr. Hayashi was careful to point out that 
FQHCs are not the same as a community health center; although they have 
some common characteristics. 
 
Requirements must be fulfilled to be considered a Health Center Program.  It 
must be located in or serve a high-needs community and governed by a 
community board composed of a majority of health center patients, who 
represent the population served.   It must also provide comprehensive primary 
health care services, as well as supportive services that promote access to 
health care.  Programs must provide services available to all on a sliding-fee 
scale and meet other performance and accountability requirements regarding 
administrative, clinical, and financial operations.  
 
There are about 9,000 clinics around the U.S., and 1200 organizations funded by 
the program.  The pie charts below were presented to illustrated ages served and 
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A snapshot of the 2011 Health Center Program’s workforce was presented.  
Below is a table detailing the workforce composition. 
Total Staff                                       
138,403  
 
Physicians                                          
9,936  
 Family/General P. 5,034  
 Internal Med 1,607  
 Pediatrics 2,010  
 Ob/Gyn 979  
 Other MD/DO 306  
 
Mental Health                                     
4,486  
 Psychiatrists 401  
 Clinical Psychologists 403  
 Clinical Social Workers 1,394  
 Other Licensed MH 1,006  
 Other MH 1,282  
 
Nurse Practitioners                             
4,186  
Physician Assistants                           
2,194  
Certified Nurse Midwives                       
553  
 
Substance Abuse                                  
874  
Pharmacy                                           
2,999  
Vision                                           
298  
 Ophthalmologists 30  
 Optometrists 134  
 Other Vision Care Staff 134  
 
Nurses                                              
11,854  
Other Med                                        
17,711  
Lab/X-ray                                            
2,778  
 
Other Professional                                  
977 
Program Enabling Services              
12,504  
 (Case Managers, Education, 
Outreach, Transport, etc.)  
 
Dental                                               
10,338  
 Dentists 3,096  
 Hygienists 1,285  
 Assistants 5,957  
 
Other Program/Services                     
4,256  
Patient Support Staff                        
23,596  
 
Management and Support Staff        
13,875  
Fiscal and Billing Staff                         
9,261  
IT Staff                                                 
2,180  
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The goal of the Health Center Program is to provide comprehensive care. 
 
The Health Care for the Homeless Program (HCH) was authorized under section 
330(h) of the Public Health Service (PHS) Act.  The Homeless Program affords 
individuals and families experiencing homelessness with high-quality, 
comprehensive, primary health care services and innovative programs and 
outreach.  In addition to the primary health care, substance abuse services are 
required to be available and provided, if needed.   In 2011, 825,295 patients had 
over 4 million encounters with the program.  At that time, 221 HCH grantees 
were located in the 50 states, DC, and Puerto Rico .  The following chart was 
presented to illustrate the growth in the number of homeless persons served by 




Below are some statistics pertaining to Health Care for Homeless Program: 
 221 HCH grantees in all 50 states, DC, and Puerto Rico  
 825,295 patients served at HCH grantees (1,087,431 total homeless 
patients served at Health Centers)  
 90.4% below 100 percent poverty level  
 62.4% uninsured  
 27.7% enrolled in Medicaid or SCHIP  
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A table was also provided showing the number of patients diagnosed among all 
grantees and also by HCH grantees.   For tuberculosis, 6,816 people were 
diagnosed over all the grantees.  Of that number, 1,265 were diagnosed by an 
HCH grantee.  Some individual may be underreported due to co-morbid 
conditions.  What the table illustrated was that HCH patients were sicker and 
poorer. 
 
The Bureau of Primary Health Care Quality Strategy has five activities and 
approaches:  Policies and Programs, Funding, Technical Assistance, Data and 
Information, and Partnerships and Collaboration.   The aim is provide better care 
and affordable care and produce healthy people and communities.  To achieve 
this a stepwise approach has been adopted.  It includes access, comprehensive 
services, and integrated care all within an integrated health system.    
 
The Bureau’s work is a collaborative effort and depends on technical assistance 
resources like: 
 National and state-based support for training and technical assistance:  
o National Cooperative Agreements  
o State/Regional Primary Care Associations  
o State Primary Care Offices  
 Federal TA Support:  
o Project Officer  
o TA Calls/Trainings  
o Onsite Consultant Support  
o BPHC TA Website  
 
More information regarding BPHC technical assistance can be found at 
http://www.bphc.hrsa.gov/technicalassistance/index.html.   
 
Healthcare for the Homeless  
Mr. John Lozier 
Executive Director, National Health Care for the Homeless Council 
 
The National Health Care for the Homeless Council is a 28-year old non-profit 
based in Nashville, Tennessee comprised of 125 organizational members and 
greater than 2,000 individual members from the HCH Clinicians’ Network, 
National Consumer Advisory Board, and Respite Care Providers’ Network.  The 
mission of the Council is to eliminate homelessness by ensuring comprehensive 
health care and secure housing for everyone. 
 
In order to achieve its mission, the Council strives to create and disseminate 
knowledge regarding the interaction of inadequate housing and poor health.  It 
also works to maintain active relationships with a broad range of service 
providers, consumer and advocacy groups, academic institutions, and public 
officials, in the United States and internationally.  It promotes clinical practices 
and public policies that will improve the health status of people without homes or 
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at risk for homelessness.  Lastly, it demonstrates its commitment to human rights 
and adherence to its Founding Principles in its activities, governance structure, 
internal policies, and external partnerships. 
 
The Council considers itself to be a human rights organization and pulls its 
principles from Article 25, the Universal Declaration of Human Rights, which says 
everyone has the right to a standard of living adequate for the health and well-
being of oneself and one’s family, including food, clothing, housing, and medical 
care. 
 
The Council provides services such as technical assistance and training, 
research, policy analysis and advocacy, and peer support.  More information 
about the Council’s service can be found at www.nhchc.org.  
 
The Council tries to address the social determinants of health.  Social 
determinants of health, for the homeless, cause a ripple effect.  Poor health 
causes homelessness.  Homelessness causes poor health, and homelessness 
complicates treatment.  The homeless experience excessive morbidity.  All 
conditions are 3 to 6 times the rate of the general public.  These individuals also 
experience premature mortality, with a life expectancy 30 years less than the 
general public.   
 
Mr. Lozier presented statistics to compare and contrast the condition of the U.S. 
in the 1980s compared to now.  In the 1980s, there was an increase in 
homelessness due to the recession experienced under President Reagan’s 
administration.  There was: 
 10% unemployment, 15% poverty 
 75% reduction in HUD budget 
 Mental health deinstitutionalization 
 Baby boomers reaching adulthood 
 Traumatized veterans 
 Appearance of AIDS 
 12.9% un-insurance (1987) 
 
The parallels of 2013 are very similar.  The numbers show: 
 7.5% unemployment, 15% poverty 
 Housing crisis reaches middle class 
 Behavioral health care insufficiency 
 Boomer’s children reaching adulthood 
 Traumatized veterans 
 50,000 new AIDS cases per year 
 15.7% un-insurance 
 
The Council has learned that housing is health care.  Therefore, the Council has 
taken on an initiative called Housing First.  The Council believes the first priority 
is to provided individuals with a home and then fix the other confounders of 
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homelessness.  Individuals tend to do better and adhere to treatment if their 
housing status is stable.  
 
Health Care for the Homeless has practice models, which are patient-centered 
and trauma-informed, with multi-disciplinary teams that can address many issues 
. The outreach orientation creates access to care, and the systems perspective 
is, again, to address the social determinants.  Grantee organizations span 
several expertise, such as:  
 Community Health Centers 
 Migrant Health Centers 
 Farmworker Health Centers 
 Public Health Departments 
 Hospitals 
 Other Community Organizations 
 
The HCH provide TB screening for shelter admission and provide a great deal of 
education and training.  Some of the HCHs provide radiology services and 
engage in treatment efforts.  They also try to support outbreak investigations. 
 
Medicaid Expansion is now a state option.  Everyone less than or equal to 138% 
of FPL or $15,500 are federal match 100% for the first 3 years, with access to 
care.   Most states in the Southeast and Southern Midwest have opted not to 
expand.  Under ACA, eligibility determination does not require individuals to 
have: 
 No home address 
 MAGI—IRS 
 Citizenship/residency—SSA 
 Online, in person, by telephone, on paper 
 Annual re-determination 
 
Navigators are provided to assistant individuals through the new ACA plan and 
assisters are funded through the marketplaces.   
 
ACA has requirements for outreach.  The law requires states “establish 
procedures for outreach and enrollment activities to vulnerable and underserved 
populations” (ACA §2201) 
 Children  
 Unaccompanied homeless youth 
 Children and youth with special health care needs 
 Pregnant women 
 Racial and ethnic minorities 
 Rural populations 
 Victims of abuse or trauma 
 Individuals with mental health or substance-related disorders 
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In order to continue the work of the Council, which includes assisting in TB 
control efforts, several things will have to be considered.  Heath Centers will 
need to continue to increase their capacity.  It needs to be remembered that 
essential community provider inclusion in panels is not guaranteed.  Also, more 
very poor people will have Medicaid, which will increase primary care 
relationships and will need to include substance abuse treatment.  He also asked 
ACET to remember that housing is health care. 
 
The floor was opened for discussion. 
 
Dr. Levin said, according to the map, health care centers are lacking in the 
Mexico-U.S. border region.  Dr. Hayashi replied the number of health canters 
reflect the populations in that area.  However, what is concerning is the number 
of places, where healthcare centers do not exist, like the Rocky Mountain area.   
Additional funding is being provided for those communities, but the caveat is the 
grant selection process, which is competitive.  HHS is looking for ways to ensure 
those areas do get the HCHs they need. 
 
Dr. Thanassi asked how Mr. Lozier’s council reduces reduplication of efforts with 
other government agencies, when addressing the homeless population and if 
they coordinate with other agencies.   He replied the council is very lean and tries 
to leverage as many additional resources as possible through leadership, so a lot 
of collaboration takes place between the council and government agencies. 
There has been, for example, much collaboration with the VA because of the 
overwhelming needs of the veterans, and there is plenty of work to go around. 
 
Dr. Castro said there is a vast array of FQHCs or look-a-likes.   The concern is 
proficiency in expertise to sufficiently diagnosis and treats TB.  He doubted they 
would be found in all of those centers.  He suggested DTBE partner with the 
program to make sure those expertise are available.   DTBE could also assist in 
recruiting health centers, which are resisting change, to make sure the right and 
appropriate services are provided.  Dr. Hayashi welcomed the opportunity.  
Health centers also require guidance on quarantine matters.  Health centers are 
utilized by children and others, who could be at risk of catching TB from patients 
presenting to the center for treatment or diagnosis.  Mr. Lozier also welcomed the 
opportunity to work in collaboration with DTBE. Transport issues are an area they 
need assistance with for homeless individuals, who are not able to access an 
HCH in close proximity.     
 
U.S./MEXICO BORDER HEALTH 
 
TB efforts along the U.S./Mexico Border  
Mr. Paul Dulin 
Director, Office of Border Health  
Delegate of the Secretary, New Mexico Department of Health to the U.S.-Mexico 
Border Health Commission 
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TB is one of the top priorities of the U.S.-Mexico Border Health Commission 
(BHC).  The BHC established the U.S.-Mexico TB Consortium and Legal Forum 
as a medium for addressing TB issues in the border region.  In 2010 and 2011, 
the BHC convened two annual meetings of the U.S.-Mexico TB Consortium and 
Legal Forum, which consisted of presentations in a conference setting.  In 2012, 
the annual meeting was changed into a workshop format, with work groups 
formed around three major themes:  
 Legal issues limiting effective TB treatment 
 Continuity of care in the binational border region 
 MDR-TB  (this was the first meeting to address clinical issues)   
 
U.S. law gives the right to detain an individual for refusal of treatment.  In Mexico, 
there is a statute to isolate the patient, but if the patient refuses treatment, the 
Human Right Laws, which says the patient can refuse treatment, trumps the 
statute.   
 
Members of the TB Consortium come from both the United States and Mexico. 
Below is a list of agencies that are part of the Consortium. 
 
United States Mexico 
 U.S. Section of the BHC 
 CDC/DTBE  and DGMQ 
 DHS/ICE 
 DOJ/BOP and USMS 
 Regional and State TB programs 
and Legal Counsels of TX, NM, 
AZ, CA 
 Border county TB programs of 
TX, CA and AZ  
 Heartland National TB Center 
 Migrant Clinicians Network 
 Cure-TB 
 PAHO US-MX Border Field 
Office 
 
 Mexican Section of the BHC 
 Federal Secretariat of Health 
Mycobacterium Program and 
Legal Affairs 
 Secretariat of Foreign Affairs 
Consulates in border region 
 National Migration Institute  
 TB Programs and Legal 
Counsels of State Health 
Secretariats of TAM, NL, COH, 
CHIH, SON, and BC 
 
 
At the 3rd Annual Meeting of the U.S.-Mexico Border TB Consortium, three 
binational work groups were established.  The TB Legal Issues deal with public 
health law regarding treatment of non-compliant TB patients and U.S. states’ 
statutes and precedents to ensure treatment.  Continuity of Care’s looks at 
continuity of treatment for patients under TB therapy being deported to Mexico or 
transferred to the Mexican authorities.  The Binational Consultative Network of 
MDR-TB Experts is a forum created for binational consultation on treatment and 
formularies for drug resistant patients.  A series of action items were proposed 
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for each work group and presented to ACET in the form of resolutions.  [See 
Resolutions under the Business Section.] 
 
The 4th Annual Meeting of the U.S.-Mexico Border TB Consortium work group 
breakouts convened for the first full day.  Presenters provided foundational 
material for discussion.  A list of tasks was presented to each work group based 
on action items proposed the previous year.  Each work group prepared a three-
year operational plan to implement activities related to their respective action 
items.  The work groups also named co-chairs to serve as focal points for 
convening quarterly virtual meetings and compiling deliverables. 
 
One of the products to be developed by the TB Legal Issues Work group is a 
“Guidebook of Legal Procedures to Facilitate Management of TB Patients in the 
U.S.-Mexico Border Region” (with emphasis on treatment of non-compliant TB 
patients).  The guidebook will be produced in collaboration with the legal 
counsels of selected U.S. and Mexican State Health Departments, DHS/ICE, and 
Mexico Health Secretariat.  The Co-Chairs are Polly Price, Professor of Law and 
Associated Faculty, Emory University (U.S.) and Lic. Agustín Herrera, Director, 
Human Rights and Health Law Investigation, Mexico Secretariat of Health (MX). 
 
Actions for the Continuity of Care Work group include creating uniform standards 
for meet and greet transfers of TB patients deported to Mexico by DHS/ICE, 
DOJ/BOP and USMS, as well as local and state detention facilities.  The 
standards will deal with reception, as well as aligning follow-up and continuity of 
care in Mexico through the Mexican Consulates, National Migration Institute, and 
local and state health jurisdictions.  They will then be disseminated to the TB 
Controllers in the United States.  A third party evaluation of all binational TB 
programs will be conducted and the definition of a binational case (U.S.-Mexico) 
will be determined.  The Co-Chairs are Diana Elson, DrPh, Chief, Epidemiology, 
DHS-ICE/ERO/ IHSC, Dept. of Homeland Security (U.S.) and Dr. Martin 
Castellanos Joya, Director, National Mycobacterium Program, Mexico Ministry of 
Health (MX).  
 
Lastly, the Binational Consultative Network of MDR-TB Experts developed 
agreements on convening and consultation procedures among state and federal 
authorities.  Meetings will be scheduled and assembled possibly quarterly and 
include select members at the regional level to review cases.  The work group 
will identify and share resources [This does not imply that the U.S. will fund all 
resources to Mexico.] and develop training of clinicians in MDR-TB treatment 
strategies and formularies, through national TB training centers, and virtual 
technologies.  Co-Chairs will be appointed by their respective federal TB 
programs. A matrix has been developed to explain the work plan.    
 
The following recommendations from the BHC were presented to ACET.  These 
recommendations were also used to formulate the resolution.   
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 Embrace the efforts of the U.S.-Mexico Border TB Consortium and 
support the implementation of its work plans as a basis to resolve 
binational TB issues 
 Consider advising the Secretary of HHS to support alignment of the 
priorities and strategies of ACET, NTBC, CDC and the OGA/U.S.-Mexico 
Border Health Commission with those of the Consortium for TB 
management in the border region 
 Consider advising the Secretary of HHS to reach out to her counterpart 
Secretary of Health in Mexico to advocate for Mexico’s continued 
participation in the TB Consortium and support to implement the work 
groups operational plans   
 Consider advising the Secretary of HHS to allocate additional funding and 
technical assistance to support activities included in the TB Consortium 
Work Group Operational Plans  
 
Dr. Seaworth said without some medication resources, it would be hard to move 
forward on specialized and individualized treatment of XDR cases.  Finding a 
way to support the resources would be the smartest strategy. 
 
Dr. Elson felt lessons learned from the correctional presentation yesterday made 
it evident that education is needed for local health departments and law 
enforcement, on continuity of care for inmates.  It would also help law 
enforcement to be able to identify potential TB cases in their populations. 
 
Dr. Dorman requested further information on CDC’s roles and it interaction with 
the Consortium.  Mr. Dulin informed the binational program is funded largely on 
the U.S. side, partially by CDC.  One of the issues the Consortium is trying to 
resolve is consistency.  In silos, everyone has developed its own practices and 
standards.  The Consortium is creating common standards to address treatment 
processes, sovereignty issues, and create a more systematic and evidence-
based practice for the programs. 
 
Dr. Castro said Mexico should be providing resources, as well, to address this 
issue.  From the TB side, DTBE could recruit TB coordinators at CDC. They may 
be helpful, as well as others at CDC, who could leverage activities.  Mr. Dulin felt 
the partnership with PAHO was been a missed opportunity.  The commission 
could have done more to align work plans in 2008.  There was a request at the 
Border Governors Conference for governors to meet with PAHO, but it never 
came to fruition; therefore, PAHO facilitated the connections themselves.   
 
Dr. Elson said an additional complexity is the Consortium focuses on individuals 
in the border areas, but there are no efforts to support treatment at their homes.  
When deported individuals return home, some further mechanism should be 
employed to ensure treatment is received.  Another point to remember is that 
Mexicans are not the only people who cross the border, and the same issue 
applies for those individuals as well. 
 
 
Advisory Council for the Elimination of Tuberculosis 
Centers for Disease Control and Prevention 
June 4 - 5, 2013   
59 
 
The meeting was called to order at 11:01 AM, after a break.  Dr. Dean conducted 
a roll call and determined that quorum was present.   
   
BUSINESS SESSION: MOTION TO ACCEPT MINUTES OF MARCH 5, 2013 MEETING 
 
ACET members, ex officio members, and liaison representatives were all 
provided a copy of the minutes from the March 5, 2013 meeting held in Atlanta, 
GA, via webinar.  Only members were permitted to vote on the minutes.  Mr. 
Jones asked for a motion to accept the minutes from the March meeting, as 
presented and provided to the members.  A motion was placed by Ms. Barbara 
Cole and seconded by Dr. C. Robert Horsburgh, Jr. Ms. Cole requested a status 
update on the Letter to the Secretary of Health.  Mr. Jones is in the process of 
finalizing the letter.  He has received all requested supplementary reports from 
the members.  He will complete the letter before his term ends, at the end of the 
month.  He will then turn the letter over to DTBE for it to be vetted through 
MASO.  From that point, MASO will forward the letter to the Secretary of Health. 
Copies of the letter will be distributed to the members, ex officio members, and 
others.  No further discussion was requested by members. ACET unanimously 
approved the motion, with no members abstaining. 
 
Forms were provided to members, who had travel orders to participate in the 
meeting.  The forms are to be submitted no later than five working days from the 
close of the meeting.  Forms should be emailed to VIM7@cdc.gov, attention 
Maureen McDermott.  Ms. McDermott’s information was also displayed on the 
overhead projector, at the conclusion of the meeting.    
 
POTENTIAL BUSINESS ITEMS 
 
Number of Meetings - Reduce to One In-Person and Two Webinars 
 
Dr. Dean provided information on a recommendation to reduce the number of 
meetings to one in-person meeting and two webinars.  The request was made 
due to budget constraints that are being experienced across the agency.  The 
Directors Committee has also adopted the new meeting schedule to one in-
person meeting and webinars.  The new proposed meeting schedule was placed 
before ACET for discussion.  
 
Number of Liaisons and Ex Officio Members 
 
Regarding the number of liaisons and ex-officio members, more clarity is needed; 
therefore, Dr. Dean passed over this portion of the meeting and moved to travel. 
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Due to budget constraints, the Committee Management Office has advised 
ACET to discuss eliminating the cost of travel for liaisons and ex-officio 
members.  If agencies and organizations cannot bear the brunt of travel cost, the 
Office is asking for those expenses to be eliminated.  Ex Officio members were 
asked to speak with their agencies about picking up those expenses, or ex officio 
members could participate, in the meetings, via conference call. 
 
Mr. Jones then opened the floor for discussion.   
Dr. Reichman felt the comments were very necessary; but the American College 
of Chest Physicians has no interest in tuberculosis.  He will provide the college 
with a copy of the minutes, once they are approved, but he was very certain that 
the college would not want to pay for his travel.  He felt DTBE would need to 
determine if it was important to continue to foster relationships. He pledged to 
participate by phone if he was not able to physically attend.  Dr. Elson’s agency 
also has travel restrictions but she committed to attending via the phone, as well.   
 
Dr. Castro responded that it is very appropriate to have CDC to support travel, 
but due to budget constraints, drastic decisions had to be made.  CDC, in fact, 
has suspended all staff travel to conferences, for the remainder of the calendar 
year.  Since quorum is essential to conduct a meeting, CDC will be looking at 
other methods and technologies, like webinars, that can solve the problem.  
Once funding has returned to normal, travel again will be supported by CDC. 
 
Dr. Dorman concurred with both Dr. Reichman’s and Dr. Castro’s comments but 
was concerned about the lessening in meeting quality, as well as the outputs.  
Dr. Benjamin also believed that in-person meetings yielded better productivity 
and that DTBE should do as much as possible to preserve in-person meetings. 
 
ACET members made some cost-saving suggestions.  Dr. Burgos suggested 
putting ACET meetings closer to the NTCA meetings and maybe that would 
provide some savings to the member’s agencies, if they did have to pay for 
travel.  Ms. Levin observed that 21 of those in attendance were from Washington, 
D.C.  She proposed that CDC come to Washington, D.C. and believed the 
change would also provide a cost savings because it would eliminate hotel and 
food costs.  
 
That option had already been considered according to Mr. Jones.   Dr. Castro 
and Dr. Dean have run some numbers and found that it is worth reconsidering 
that option.  The Federal Tuberculosis Taskforce Meeting occurs in Bethesda, 
MD at NIH facilities because a majority of its members lives in that area.  He felt 
it would be worth writing a letter to the Secretary of Health to consider this option.  
DTBE will do an official cost comparison.   The option may prevent several key 
individuals at CDC, from attending.  Dr. Baine advised DTBE to speak to the 
Healthcare Infection Control Practices Advisory Committee (HICPAC), who has 
also reduced their number of meetings and have been for some time.  They may 
have some cost-savings estimates that they could share. He also did not believe 
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that his agency would support paying the cost for him to attend ACET meetings, 
as they already do not support his trips to HICPAC meetings.  
 
Ms. Bur suggested using the Corrections Work Group model, which has proven 
to be efficient and is leading to real change.  Members of the work group met on 
the phone to achieve its mission.  She felt the current fiscal constraints were an 
opportunity for DTBE to figure out a way to do things differently, such as using 
small work groups to do more intensive work via the telephone.  The process 
would also yield more well prepared and thought-out material.  Mr. Jones 
concurred with Ms. Bur’s comments.  Meetings should be used to advance 
policies, said Mr. Jones, and not just to hear presentations of updates.  He 
suggested the new chair and the Agenda Review Committee move to that type of 
process.  Ms. Cole agreed with Mr. Jones’ suggestions and felt subcommittees 
could be assign to certain task, and at the in-person meetings, present their 
outcomes to be vetted by ACET.  Any updates could be submitted in the form of 
reports versus presentations.   
 
Dr. Reichman asked DTBE to forward a communicate either from Dr. Dean, Dr. 
Frieden, or the Secretary of Health explaining why participation was important 
enough that members’ agencies should support travel expenses.   
 
Mr. Jones, before closing discussion on the travel topic, again recommended 
ACET continue to talk about ideas on how to conduct future meetings.  Dr. Carter 
was heading a work group, who was examining options to overcome this 
problem.  The Agenda Committee was one of the outputs from the work group.  
The second recommendation from the work group was to use in-person meetings 
for advancing policy and only hear updates that were essential.   More specificity 
is needed on what day one of the meeting will entail and leaving day two for 
business only.  Therefore, he queried the committee and asked if it felt another 
similar work group should be put together, who can decide the components of a 
typical meeting.    
 
Dr. Narita said the complexity of some resolutions demanded discussion among 
the committee and DTBE to gain more understanding.  Mr. Jones said a possible 
agenda item could be a report on what actions have been taken, since the 
resolution. 
 
Dr. Horsburgh, Jr. did not feel a new work group was warranted.  The Agenda 
Committee could take on that role.  Mr. Jones directed the Agenda Committee to 
meet soon and to make sure deliverables are focused on policy type of 
discussion, in light of what has been discussed at this meeting.   
 
Dr. Castro reminded the Committee of the rule, which says members may not 
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Dr. Roselle observed the current meeting format and found it to be backwards. 
Most meetings he has attended handle business on day one and leaving day two 
for presentations.  The business decisions that ACET makes demand that the 
group be energized so that it may weigh in on very important topics.  As it is now, 
business is conducted on the second day and members are either exhausted or 
disengaged or have to leave early to catch flights back home, which threatens 
quorum.  Mr. Jones charged the Agenda Committee to put future meetings in Dr. 
Roselle’s prescribed format.   
 
Dr. Benjamin proposed using a webinar just before the in-person meeting to 
present any background information or updates.  In-person meetings could 
contain discussion of what was learned through the webinar, as well as, to 
conduct the business session.  Mr. Jones also added the suggested format to the 
Agenda Committee’s charge.  Dr. Baine hoped that members would come to the 
meeting prepared by being sure to review any pre-presented information so rich 
discussions could occur.   
 
Dates for next ACET meeting -December 3-4, 2013  
 
Mr. Jones said the anticipation was to have a meeting in October and December.  
The October meeting would be a webinar and the December meeting would be 
the annual.  Mr. Jones asked if the October webinar was needed or should the 
committee just defer to the December meeting. 
 
Dr. Castro thought Dr. Benjamin’s suggestion should be employed and to use the 
October meeting as the webinar for updates and presentations, which can guide 
policy discussions at the December meeting.  Ms. Scott-Cseh will provide dates 
for the October webinar.  The December meeting will be on the 3rd and 4th.    
 
Ms. Bur will facilitate efforts to find one location for all D.C. attendees to gather 
for the October webinar.  The same process will happen for Atlanta but no one 
was identified to head those efforts.   
 
The committee stopped, momentarily, to pick up lunch and continued the 
meeting over a working lunch.  A roll call was taken to ensure quorum was 
present. 
 
INTERNAL ACET DISCUSSIONS 
Resolutions 
 
The Committee reviewed six resolutions.  The first was presented by Ms. Cole 
entitled TB Screening for H-1B Work Visa Applicants, which was a collaboration 
among the California Tuberculosis Controllers Association (CTCA), the National 
Association of City and County Health Officials (NACCHO), and the National 
Tuberculosis Controllers Association (NTCA).  The resolution was brought forth 
in light of the Immigration Bill that is before Congress.  The collaborative felt it 
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important to look at H-1B work visa applicants.  Work visa applicants may work 
up to three years and in some cases up to six.  The resolution proposes 
screening recommendations for this population.   
 
Ms. Cole read the resolution.   
 
TB Screening of H1B Work Visa Applicants 
 
 
WHEREAS the Immigration Bill currently before Congress 
proposes to increase the number of H1B work visas from the 
current 65,000 to approximately 180,000 applicants yearly, 
 
WHEREAS there is currently no requirement for H1B work visa 
applicants or their families, to receive any health screening prior to 
migration to the United States, 
 
WHEREAS many H1B work visa applicants come from countries 
with high prevalence of tuberculosis (TB) and drug resistant TB, 
 
WHEREAS ACET recommends that  health screening for 
Tuberculosis and other communicable diseases for all H1B work 
visa applicants and any family members planning to migrate to the 
United States under the H1B visa program be implemented 
overseas, by approved Panel Physicians, in compliance with the 
current Technical Instructions, prior to travel to the United States. 
 
WHEREAS ACET further recommends that the cost of the 
overseas, pre-migration screening of the H1B work visa applicant 
and any family member(s) planning to migrate under this program, 
be borne by the company sponsoring the H1B work visa applicant, 
and that prohibitions/restrictions on travel/migration be the same as 
applies to current immigrants based on health screening. 
 
Be it now resolved that ACET recommends that:  
1. H1B work visa applicants be screened for TB and other 
communicable diseases in compliance with the current 
Technical Instructions prior to travel to the United States. 
2. CDC informs HHS Secretary Sibelius of this resolution and 
recommends that she take appropriate action to inform 
congressional members working on the Immigration reform 
bill. 
 
Mr. Jones asked for a second to accept the resolution. The motion was seconded 
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Dr. Brenner asked for the verbiage “prior to issuance of H-1B visa” be added to 
the resolution and delete travel to the U.S.  The change was made throughout 
the document where needed.  The additional verbiage “implemented overseas, 
by approved Panel Physicians, or in the U.S. by Civil surgeons, in compliance 
with the current Technical Instructions” was also added. 
 
Ms. Napolitano supported the resolution on behalf of Stop TB USA.  Dr. Trump 
also supported the resolution on behalf of the Council for State and Territorial 
Epidemiologists (CSTE).   
 
Dr. Narita asked if the resolution would void a decision made by his agency to 
test anyone who plans to stay in the United States for more than six months.  Ms. 
Cole replied the resolution stands on its on and would not.  
 
Dr. Elson asked if the resolution would restrict travel for individuals who are 
screened in the United States and found to have TB.  According to the Technical 
Instructions, those individuals would have to remain in the country of origin until 
they completed treatment without the waiver.   Dr. Levin thought the model used 
in Australia would work, in this case.  In the model, any individuals found positive 
with latent or active TB are treated in Australia at the government’s expense.  
Ms. Cole said the United States would handle active cases as normal and 
intervene.  Dr. Narita reminded the group that the process the resolution 
proposes will cause increases in H-1B, H-2B, and H-3B.   
 
After a few additional minimal changes, Ms. Cole re-read the resolution. 
 
TB Screening of H-1B Work Visa Applicants 
 
WHEREAS the Immigration Bill currently before Congress 
proposes to increase the number of H-1B work visas from the 
current 65,000 to approximately 180,000 applicants yearly, 
 
WHEREAS there is currently no requirement for H-1B work visa 
applicants or their families, to receive any health screening. 
 
WHEREAS many H-1B work visa applicants come from countries 
with high prevalence of tuberculosis (TB) and drug resistant TB, 
 
WHEREAS ACET recommends that  health screening for 
Tuberculosis and other communicable diseases for all H-1B work 
visa applicants and any family members prior to issuance of  a H-
1B visa be implemented overseas, by approved Panel Physicians, 
or in the U.S. by Civil surgeons,  in compliance with the current 
Technical Instructions. 
 
WHEREAS ACET further recommends that the cost of screening of 
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the H-1B work visa applicant and any family member(s)  be borne 
by the company sponsoring the H-1B work visa applicant, and that 
prohibitions/restrictions on travel/migration be the same as applies 
to current immigrants based on health screening. 
 
Be it now resolved that ACET recommends that:  
1. H-1B work visa applicants be screened for TB and 
other communicable diseases in compliance with the 
current Technical Instructions prior to issuance of H-
1B visa. 
2. CDC informs HHS Secretary Sebelius of this 
resolution and recommends that she take 
appropriate action to inform congressional members 
working on the Immigration reform bill. 
 
Dr. Seaworth seconded the resolution.  ACET unanimously approved the 
motion, with no members abstaining.  Dr. Cole gave special thanks to Dr. 
Benjamin, who was first to propose the resolution. 
 
Dr. Seaworth presented two resolutions.  The first was regarding bedaquiline.  
Dr. Seaworth read the resolution.  
 
Bedaquiline, the first new class of drug to be approved for 
treatment of tuberculosis in over 50 years, was granted accelerated 
approval by the FDA in December 2012.  On January 15, 2013 the 
CDC held a consultancy with external experts to develop guidelines 
for the use of this drug.  These guidelines have passed through 
CDC clearance.  ACET recommends that they be published 
immediately in the MMWR in order to provide guidance to programs 
and providers to ensure proper use of the drug in the correct patient 
populations, and to ensure proper monitoring.  
 
Mr. Jones suggested the paragraph be split into two paragraphs starting at 
ACET.  He then called for a second to the motion.  Dr. Narita seconded the 
motion.  The floor was opened for discussion. 
 
Dr. Brenner asked if the resolution was proposed for the record or out of fear that 
the MMWR publication may be delayed.  Dr. Seaworth said the cue for MMWR 
publications is very long and the resolution was part of what FDA instructed the 
company to do, which was to work with CDC to develop guidelines for the use of 
the drug.   The drug is not yet available, and the resolution could expedite the 
process. Dr. Castro said the guidelines have been written and cleared by the 
Office of the Associate Director at CDC.  Because of the cue in the MMWR, it 
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Ms. Cole supported the resolution but felt the cost would be a barrier because 
the manufacturer has mandated that 188 tablets must be purchased upfront, with 
a cost of approximately $23,000.  Dr. Castro advise Ms. Cole to reach out to the 
Treatment Action Group (TAG) or other outside advocates to bring the issue to 
the forefront. 
 
Dr. Horsburgh, Jr. proposed that CDC put the resolution online, prepublication.  
Dr. Castro said it could be a plan-B effort or ACET could amend the resolution to 
say if immediate publication is not evident in the foreseeable future, consider 
posting online.  Verbiage was added to the resolution as Dr. Castro prescribed.   
 
Dr. Dorman asked if the guidelines has been vetted through the CDC process.  
Dr. Castro was pretty certain that the guidelines have been shared.   The 
guidelines, however, are not co-authored by the expert panel according to the 
Federal Advisory Committee Act (FACA) Rules.  Dr. Seaworth added that, as 
one of the consultants who was part of the development of the guidelines, 
comments were not shared with consultants.   Dr. Baine advised adding the 
verbiage “ACET recommends that if immediate publication of the guidelines for 
using bedaquiline”.    
 
Dr. Reichman felt the new drug alert was just as important as a new side effect 
publication and wondered if new drugs follow the same precedence.  Dr. Castro 
replied the drug would be announced in some shape or form even if it did not 
make immediate publication in the MMWR.   
 
Since physicians are not able to write prescriptions for bedaquiline, Dr. Tompkins 
wondered how the resolution would help.  Dr. Seaworth had a patient who 
started on the drug in April and is still going through the Compassionate Use 
Process.  The availability of the drug is resting on Janssen Therapeutics 
identifying a distributor and putting in place mechanisms for distribution.  A 
consultation with experts is also still needed and extent guidelines for use 
labeling process has not occurred.  Dr. Castro believed those were the only 
issues preventing physicians from writing prescriptions for the drug.  Dr. 
Seaworth’s understanding was that guidelines and a registry was delaying the 
process.  Dr. Castro will check with Dr. Mase for more information.  
 
After a few minor edits, Dr. Seaworth re-read the resolution. 
 
Bedaquiline, the first new drug to be approved for treatment of 
tuberculosis in over 50 years, was granted accelerated approval by 
the FDA in December 2012.  On January 15, 2013 the CDC held a 
consultancy with external experts to develop guidelines for use of 
this drug.  These guidelines have passed through CDC clearance.   
 
ACET recommends that if immediate publication of the bedaquiline 
guidelines in the MMWR cannot accomplished, then they should be 
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published on line in order to provide guidance to programs and 
providers to ensure proper use of the drug in the correct patient 
populations, and to ensure proper monitoring.  
 
The motion was seconded by Dr. Horsburgh, Jr.  ACET unanimously approved 
the motion, with no members abstaining. 
 
Dr. Seaworth then presented her second resolution.  The resolution was 
developed in conjunction with Dr. Burgos and Mr. Dulin to support the work plan 
developed by the U.S.-Mexico Border TB Consortium. 
 
Whereas the burden of tuberculosis is higher in the U.S.-Mexico 
Border Region than in any other region of either Mexico or the U.S.; 
 
Whereas the U.S.-Mexico border region is an area with a high 
prevalence of drug-resistant TB that can easily be transmitted to 
persons in the US.;   
 
Whereas, the U.S.-Mexico Border TB Consortium was established 
under the auspices of the U.S.-Mexico Border Health Commission, 
and whose members have developed a three-year operational work 
plan to implement a series of actions aimed at reducing barriers to 
successful treatment of TB in the binational border region; 
 
Be it resolved that ACET embraces the efforts of the U.S.-
Mexico Border TB Consortium and supports the 
implementation of its work plan as a basis to resolve 
binational TB issues and  
 
Recommends that: 
(1) CDC continue to identify opportunities to address 
tuberculosis control efforts along the U.S.-Mexico Border and  
 
(2)  Advises the Secretary of Health and Human Services  
reach out to her counterpart Secretary of Health in Mexico to 
advocate for Mexico’s continued participation in the TB 
Consortium and support to implement the work group’s 
operational plans and to allocate additional funding and 
technical assistance to support activities included in the TB 
Consortium Work Group Operational Plan. 
 
Mr. Jones asked if items in the “be it resolve” section would be incorporated into 
the body of the resolution.   The Secretary, according to Dr. Seaworth, was being 
asked to support the efforts and not CDC.   Mr. Jones asked for a second to the 
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Dr. Elson felt it was more appropriate for ACET to advise the Secretary, since it 
is part of the ACET Charter and to remove “allocate funding” because that is a 
function of Congress. 
 
Dr. Narita asked if the statement in the first sentence was supported by data.  Dr. 
Seaworth confirmed it to be accurate.  Dr. Baine made minor editing suggestions. 
 
With no further discussions, Mr. Jones asked Dr. Seaworth to re-read the 
resolution proposed.   
 
Whereas the burden of tuberculosis is higher in the U.S.-Mexico 
Border Region than any other region of either Mexico or the U.S.; 
 
Whereas the U.S.-Mexico border region is an area with a high 
prevalence of drug-resistant TB that can easily be transmitted to 
persons in the US.;   
 
Whereas, the U.S.-Mexico Border TB Consortium was established 
under the auspices of the U.S.-Mexico Border Health Commission, 
and whose members have developed a three-year operational work 
plan to implement a series of actions aimed at reducing barriers to 
successful treatment of TB in the binational border region; 
 
Be it resolved that ACET embraces the efforts of the U.S.-
Mexico Border TB Consortium and supports the 
implementation of its work plan as a basis to resolve 
binational TB issues and  
 
Recommends that: 
(1) CDC identify opportunities to address tuberculosis control 
efforts along the U.S.-Mexico Border and  
 
(2)  the Secretary of Health and Human Services  reach out to 
her counterpart Secretary of Health in Mexico to advocate  
Mexico’s continued participation in the TB Consortium and 
support implementation of  the operational plan and 
 
 (3)  the Secretary of Health and Human Services recommend 
allocation of  additional resources and technical assistance to 
support activities included in the TB Consortium Work Group 
Operational Plan. 
 
Mr. Jones called for a second.  Dr. Burgos seconded the motion.  ACET 
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Dr. Dorman presented the Drug Shortage Resolution.  The resolution was 
developed, in consultation with Drs. Jennifer Flood and Sundari Mase to 
strengthen their activities, in ensuring a continuous and affordable supply of anti-
tuberculosis drugs.   Dr. Dorman read the resolution. 
 
Recommendations to ensure a continuous and affordable 
supply of anti-tuberculosis drugs 
 
The members of the Advisory Council for the Elimination of 
Tuberculosis (ACET),  
 
Determined to eliminate tuberculosis (TB) in the United States; 
 
Cognizant of the actions taken to date by the Centers for Disease 
Control and Prevention (CDC) Department of Tuberculosis 
Elimination (DTBE) to assess the extent and impact of shortages of 
anti-tuberculosis drugs; 
 
Seriously concerned that the shortage of anti-tuberculosis drugs 
persists without resolution; 
 
Alarmed especially that the shortage presently encompasses 
isoniazid, a critical component of the standard regimen for 
treatment of tuberculosis; 
 
Recognizing that longer-term strategies to prevent shortages are 
required in addition to the ongoing drug-by-drug stopgap measures  
 
Have agreed, as follows: 
 
We encourage the Secretary of Health and Human Services to 
support activities towards ensuring a continuous and affordable 
supply of anti-tuberculosis drugs.  Consideration should be given to 
establishment of a dedicated team to address this issue, 
intensification of activities to prevent drug shortages, and pursuit of 
regulatory changes that will facilitate a stable drug supply.   Strong 
consideration should be given to pursuit of a centralized 
procurement and distribution system for anti-tuberculosis drugs.   
 
The resolution was in concordance with a white paper developed by Drs. Flood 
and Mase’ team.   
 
Mr. Jones suggested the language “we recommend” be replaced by “we 
encourage”.  He then asked for a second to the motion. Dr. Seaworth seconded 
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Dr. Seaworth felt the resolution was a step in the right direction for MDR drugs.  
She reported on the model used for Texas, which has a central procurement for 
INH, and, therefore, the state experienced no drug shortages.  Pharmacies were 
made aware of potential drug shortages long before CDC announced them and 
had developed strategic plans to dealing with the matter.  A notice was provided 
in a recent Lancet article, which said the Global Drug Facility provided data 
showing a significant decrease in cost of TB drugs, since developing a single 
procurement agency to purchase drugs.    
 
Dr. Warkentin thought it would have been helpful, if Drs. Flood and Mase 
provided the white paper to the ACET prior to the committee making a decision; 
albeit, he felt there would be broad support for the resolution. Dr. Seaworth said 
her understanding was the paper was proposed but has not been written.  Dr. 
Castro confirmed it is being worked on. 
 
Dr. Dorman noted biologics were not included in the resolution, which was by 
intent, since the real issue is drugs. 
 
With no further discussion and a motion properly seconded by Dr. Seaworth, 
ACET unanimously approved the motion, with no members abstaining.  The 
resolution will read as follows: 
 
Recommendations to ensure a continuous and affordable 
supply of anti-tuberculosis drugs 
 
The members of the Advisory Council for the Elimination of 
Tuberculosis (ACET),  
 
Determined to eliminate tuberculosis (TB) in the United States; 
 
Cognizant of the actions taken to date by the Centers for Disease 
Control and Prevention (CDC) Department of Tuberculosis 
Elimination (DTBE) to assess the extent and impact of shortages of 
anti-tuberculosis drugs; 
 
Seriously concerned that the shortage of anti-tuberculosis drugs 
persists without resolution; 
 
Alarmed especially that the shortage presently encompasses 
isoniazid, a critical component of the standard regimen for 
treatment of tuberculosis; 
 
Recognizing that longer-term strategies to prevent shortages are 
required in addition to the ongoing drug-by-drug stopgap measures  
 
Have agreed, as follows: 
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ACET recommends that the Secretary of Health and Human 
Services support activities towards ensuring a continuous and 
affordable supply of anti-tuberculosis drugs.  Consideration should 
be given to establishment of a dedicated team to address this 
issue, intensification of activities to prevent drug shortages, and 
pursuit of regulatory changes that will facilitate a stable drug supply.   
Strong consideration should be given to pursuit of a centralized 
procurement and distribution system for anti-tuberculosis drugs.   
 
Dr. Horsburgh, Jr. presented the ACA Resolution to ACET.  It reads as follows: 
 
Whereas the Affordable Care Act (ACA) offers unprecedented 
opportunity to increase insurance coverage, access to care, and to 
increase healthcare quality, providing critical services to uninsured 
and high-risk populations will remain challenging;   
 
Whereas the focus to date in ACA to address chronic diseases is 
warranted given the burden and cost associated with them, it will be 
important to assure that efforts to prevent transmission of 
communicable diseases, such as tuberculosis (TB), which can 
threaten a community’s well-being, are not compromised by 
changes in care systems; 
  
Therefore, ACET urges the Secretary of Health and Human 
Services to require that CDC, CMS, HRSA, and other relevant 
federal agencies work together to develop an operational 
framework for assuring the ongoing adequacy of the safety net for 
addressing communicable diseases of public health significance.   
 
Mr. Jones called for a second to the motion.  Ms. Cole seconded the motion.  
The floor was opened for discussion.   
 
Dr. Narita felt it admirable to include other communicable disease but wondered 
if the focus should remain solely on TB.   The committee was queried the 
committee for comments.  Dr. Burgos and Ms. Cole believed the wording TB and 
other communicable disease should be used, since TB is the charge of ACET.  
Mr. Dulin asked for the insertion of the Assistant Secretary for Preparedness and 
Response (ASPR), as an additional agency, since the agency is also a major 
player in communicable disease outbreaks.  Dr. Baine again offered minimal 
edits.   
 
With no further discussion and a motion properly seconded by Dr. Narita,  ACET 
unanimously approved the motion, with no members abstaining.  The 
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Whereas the Affordable Care Act (ACA) offers unprecedented 
opportunity to increase insurance coverage, access to care, and 
healthcare quality, providing critical services to uninsured and high-
risk populations will remain challenging;   
 
Whereas the focus to date in ACA to address chronic diseases is 
warranted given the burden and cost associated with them, it will be 
important to assure that efforts to prevent transmission of 
tuberculosis (TB) and other communicable diseases, which can 
threaten a community’s well-being, are not compromised by 
changes in care systems; 
  
Therefore, ACET urges the Secretary of Health and Human 
Services to require that CDC, CMS, HRSA, ASPR, and other 
relevant federal agencies work together to develop an operational 
framework for assuring the ongoing adequacy of the safety net for 
addressing TB and other communicable diseases of public health 
significance.   
 
Ms. Cole presented the reformatted ACET Resolution presented, from day one.  




WHEREAS, accurate TB testing of medium- and high-risk persons 
is essential to TB elimination in the US, and 
  
WHEREAS, the accuracy and positive predictive value of any 
assay decreases significantly in populations with low prevalence of 
TB infection, and 
  
WHEREAS, Interferon Gamma Release Assay (IGRA) reversion 
has been commonly observed and frequently reported in low-risk 
(unexposed) healthcare workers undergoing serially testing, and 
  
WHEREAS, false-positive results can lead to unnecessary medical 
evaluation or treatment, and 
  
WHEREAS, it is recognized that the low-risk individuals should not 
be undergoing such TB testing, and 
  
WHEREAS, over testing of low-risk persons can lead to 
misdiagnosis and waste of national healthcare dollars, so 
  
BE IT RESOLVED, that ACET advises the CDC to convene an 
expert working group to urgently address the following by priority: 
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1. Management guidelines to address the variability 
observed in serial testing using IGRAs among low risk 
or unexposed adults, who are included in a mandatory 
TB screening program 
2. Stratification guidelines for HCWs based on the levels 
of TB exposure for the purpose of determining the need 
for serial testing 
3. Consideration of a retesting zone for low risk or 
unexposed individuals undergoing TB screening 
currently recommended by state law or local, state and 
national TB guidelines. 
Mr. Jones called for a second to the motion.  It was seconded by Dr. Seaworth.  
The floor was opened for discussion.   
 
Dr. Burgos expressed concerns over the amount of false positives associated 
with IGRAs and suggested the proposed team, of experts recommended in the 
resolution, make the stratification of the guidelines.  The issue, he felt, was 
outside of the expertise of the ACET.   Dr. Dorman concurred with Dr. Burgos 
and believed the scope of what ACET was to recommend was unclear.  Should 
the focus be on healthcare workers or should the vision be more broader?   Dr. 
Narita thought the context of how TB experts was expressed sounded more like 
a partnership with an occupational workforce.  Ms. Bur believed it is becoming 
unethical to treat bacilli Calmette-Guerin (BCG)-vaccinated individuals, who test 
positive on a PPD. 
 
Mr. Desmond said the public health department works with IGRAs and are very 
often asked to make an interpretation, which puts the health department in an 
awkward situation.  Therefore, he strongly supports the formation of the 
proposed working group and looked forward to its recommendations.   
 
Dr. Warkentin said the statement in bullet three must be based on the science 
and any scientific gathering around the issue or development of guidelines not be 
subject to a group convened by one of the manufacturers.  Furthermore, the 
second bullet puts into questioning the guidelines published in 2005 regarding 
testing of healthcare workers.  What may need to occur, he suggested, is a 
revision to the 2005 guidelines, in light of new technologies.  
 
Dr. Thanassi thanked Mr. Desmond for his comment and concurred with his 
opinions.  She also thanked Dr. Warkentin for suggesting that the proposed 
panel be independent of any industry influence.  Dr. Thanassi reminded the 
group that the resolution was crafted, in part, due to the findings she presented 
on day one. ACET, she said, was the perfect mechanism to make 
recommendations regarding healthcare workers not being stratified.  Ms. Cole 
said the committee would look at the issues, but an expert panel should make 
the decisions.   
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Dr. Narita preferred that healthcare worker still be spelled out.  Ms. Cole felt that 
leaving the resolution to read among low risk or unexposed adults, would still 
encompass that group.  Mr. Desmond suggested the addition of “consideration” 
be added to bullet two and three 
 
Dr. Brenner pondered if it would be easier for DTBE to conduct the panel in-
house versus turning to outsiders.  Dr. Castro said DTBE would use its normal 
approach by turning to experts and not convening panel on its own. 
 
Dr. Baines once more made minimal edits. 
 




WHEREAS, accurate TB testing of medium- and high-risk persons 
is essential to TB elimination in the US, and 
  
WHEREAS, the accuracy and positive predictive value of any 
assay decreases significantly in populations with low prevalence of 
TB infection, and 
  
WHEREAS, Interferon Gamma Release Assay (IGRA) reversion 
has been commonly observed and frequently reported in low-risk 
(unexposed) healthcare workers undergoing serially testing, and 
  
WHEREAS, false-positive results can lead to unnecessary medical 
evaluation or treatment, and 
  
WHEREAS, it is recognized that the low-risk individuals should not 
be undergoing such TB testing, and 
  
WHEREAS, over testing of low-risk persons can lead to 
misdiagnosis and waste of national healthcare dollars, so 
  
BE IT RESOLVED, that ACET advises the CDC to convene an 
expert working group to urgently address the following: 
1.       Management guidelines to address the variability observed in 
serial testing using IGRAs among low risk or unexposed adults, 
who are included in a mandatory TB screening program 
2.      Consideration of  Stratification guidelines for HCWs based on 
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3.       Consideration of a retesting zone for low risk or unexposed 
individuals undergoing TB screening currently recommended by 
state law or local, state and national TB guidelines. 
The motion was seconded by Dr. Seaworth.  ACET unanimously approved the 
motion, with no members abstaining. 
 
Dr. Dorman introduced a letter proposed by Ms. Bur to the Secretary of Health 
and Human Services highlighting the necessity of preserving capacity for 
treatment at both the individual and public health level for TB.  Dr. Dorman 
suggested that the letter should be circulated among ACET for revisions and 
edits offline and then sent forward through the appropriate mechanisms.  Dr. 
Dean made the committee aware that ACET is not allowed to conduct ACET 
business offline but that it could convene a work group.  Therefore, Dr. Dorman 
therefore made the motion that ACET convene a work group to develop a letter 
directed to the Secretary of the Department of Health and Human Services 
addressing more largely the potential impact of funding cuts on TB programs.  
Ms. Cole seconded the motion.  Mr. Jones opened the floor for discussion.   
 
Dr. Narita suggested the addition of Dr. Frieden’s name to the letter.  Dr. Dorman 
said the work group would be responsible for determining additions and then 
ACET could review the revisions and edits at the October meeting. 
 
With no further discussion, Mr. Jones called for a vote.  ACET unanimously 
approved the motion, with no members abstaining.  Mr. Jones appointed Drs. 
Dorman and Horsburgh, Jr. to form the committee and present the finalized 
document at the October meeting.   
 
CONTINUATION OF POTENTIAL BUSINESS ITEMS:  
 
Special recognition and plaques were presented to members rotating off the 
committee, by Dr. Dean, with the exception of Dr. Dorman, who will stay on the 
committee until a replacement has been identified.   
 
Dr. Horsburgh, Jr. reminded ACET of Dr. Warkentin’s request to look at the 
Essential Components of the Prevention Control Program statement and to 
consider updating it.  He wondered if a work group should be convened to 
examine the document.  Mr. Jones suggested the topic be submitted to the 
Agenda Review Committee, as a possible item for the October meeting.  Dr. 
Castro clarified his understanding of Dr. Horsburgh’s request, which was to either 
convene a working group to have already examined the document and report its 
findings at the next meeting or have the Agenda Review Committee consider it 
as an item to be added to the agenda.   
 
Dr. Brenner made the motion that ACET put together a work group to address 
revising the Essential Components of the Prevention  Control Program 
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document.  The motion was seconded by Dr. Horsburgh, Jr.  ACET 
unanimously approved the motion, with no members abstaining.   
Mr. Jones asked for volunteers for the work group.  Drs. Brenner, Burgos and 
Ms. Cole volunteered to be a part of the work group.   
 
Ms. Cole asked if resolutions could be shared once the have passed.  She would 
attend an upcoming meeting and would like to present the resolution.  Dr. Dean 
replied the meeting is open to the public; therefore, it should not present a 
problem.   
 
Mr. Jones solicited the committee for additional items to be considered for the 
Agenda Committee.  The following were proposed.   
 
 IGRAs and the changing landscape with an emphasis on 
correctional facilities 
 Understanding the timeframe for reviewing and updating previous 
recommendations to develop a current set of guidance.  What is up 
to date?  What needs to be changed?  What is the timeline and 
work plan of ACET for advancing changes? 
 Essential Components and funding reductions 
 More transparency in forthcoming guidelines with representation 
from appropriate groups, like NTCA 
 Screening and Management of TB in Foreign-Born Populations and 
Prevention of TB in Humanitarian Workers guidance documents 
 Ways for ACET to update extent policies and address new policies  
 
Dr. Trump inquired about missing minutes on the website.   To DTBE’s 
knowledge, the website did contain all the approved minutes, but staff will make 




The floor was open for public comments. Mr. Jerry (Mazverk) commended the 





Dr. Dean conducted a final roll call.  Quorum was present. 
 
Mr. Jones thanked all the participants for a joining and helping to facilitate a 
productive meeting.    He also thanked ACET for allowing him to serve the 
committee, as Chair, and wished other members leaving the committee much 
success, in their roles.  Ms. Scott-Cseh and her staff were acknowledged and 
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With no additional comments or questions posed, Mr. Jones adjourned the 
meeting at 2:19 PM. 
CERTIFICATION 
I hereby certify that, to the best of my knowledge and ability, the foregoing 
minutes of the June 4-5, 2013, meeting of the Advisory Council for the 
Elimination of Tuberculosis, CDC are accurate and complete. 
___________________    __________________________ 
              Date      Shannon Jones, III 
       Chair, Advisory Council for the 
       Elimination of Tuberculosis, CDC 
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Attachment #1: Meeting Participants  
 
Note  
Dr. Hazel Dean, ACET Designated Federal Officer, conducted roll calls on June 
4-5, 2013, at the beginning of the meeting and when the group reconvened from 
breaks. She verified the presence of a quorum for ACET voting members and ex 
officio members sufficient for ACET to conduct its business.  
 
ACET Members  
Mr. Shannon Jones III, Chair  
Dr. Eric Brenner  
Dr. Marcos Burgos  
Ms. Barbara Cole  
Dr. Susan Dorman  
Dr. C. Robert Horsburgh, Jr.  
Dr. Masahiro Narita  
Dr. Barbara Seaworth 
 
 
ACET Designated Federal Officer  
Dr. Hazel Dean, NCHHSTP Deputy Director  
 
ACET Ex Officio Members  
Dr. Naomi Aronson (Department of Defense, Uniformed Services) 
Dr. William B. Baine (Agency for Healthcare Research and Quality) 
Ms. Sarah Bur (Federal Bureau of Prisons) 
Dr. Rupali Doshi (HIV/AIDS Bureau) 
Ms. Lisa Delaney (alternate, National Institute for Occupational Safety and 
Health) 
Mr. Paul Dulin (sitting in for Dr. Antonio Falcon)(U.S.-Mexico Border Health 
Commission) 
Ms. Caroline Freeman (Office of Biologic Hazards) 
Dr. Diana Elson (US Immigration and Customs Enforcement) 
Dr. J. Nadine Garcia (Office of Minority Health, HHS) 
Dr. Warren W. Hewitt, Jr. (Substance Abuse and Mental Health Administration) 
Dr. Momodikoe Makhene (National Institute of Allergy and Infectious Diseases) 
Ms. Tiffany Moore (United States Marshals Service) 
Dr. Sheldon Morris (Food and Drug Administration) 
Dr. Gary Roselle (Department of Veteran Affairs) 
Dr. David Weissman (National Institute for Occupational Safety and Health) 
 
ACET Liaison Members  
Dr. Robert Benjamin (National Association of City and County Health Officials) 
Dr. Mayleen Ekiek (Pacific Island Health Officers Association) 
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Mr. Eddie Hedrick (Association for Professionals in Infection Control and 
Epidemiology) 
Ms. Cornelia Jervis (Treatment Action Group) 
Dr. Ilse Levin (American Medical Association) 
Ms. Eileen Napolitano (Stop TB USA) 
Dr. Edward Desmond (Association of Public Health Laboratories) 
Dr. Susan M. Ray (Infectious Disease Society of America) 
Dr. Lee Reichman (Global Tuberculosis Institute) 
Dr. Lornel Tompkins (National Medical Association) 
Dr. David Trump (Council of State and Territorial Epidemiologists) 
Dr. Jon Warkentin (alternate, National Tuberculosis Controllers Association) 
 
CDC Representatives  
Dr. Kenneth Castro, Director, Division of Tuberculosis Elimination, NCHHSTP  
Mr. Glen Christie 
Ms. Margie Scott-Cseh  
Mr. Philip Talboy 
Ms. Wanda Walton 
Dr. Beverly Metchock 
Dr. John Jereb 
Dr. Michael Iademarco 
Dr. Eugene McCray 
Dr. Andy Vernon 
Ms. Susan Robinson 
Ms. Michelle Russell 
Mr. Angel Roca 
Ms. Ann Lanner 
Dr. Salaam Semaan 
Dr. Krista Powell 
Dr. Drew Posey 
Ms. Anne Marie France 
Mr. Mark Miner 
Ms. Amera Khan 
Ms. Kim Young 
Dr. Tom Navin 
Ms. Suzanne Marks 
Mr. Gustavo Aquino 
Dr. John Douglas 
Ms. Angela Starks 
Ms. Maria Fraire Sessions 
Dr. Christina Ho 
Mr. Jerry Mazvach 
Mr. Weigong Zhou 
Dr. Awal Khan 
Ms. Brandy Peterson 
Dr. Stuart Berman 
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Ms. Haley Stolp 
Ms. Michele Pearson 
Ms. Rozina Kassam 
Ms. Lauren Lambert 
Ms. Maureen McDermott 
Ms. Demetria Gardner 
Ms. Reque Miranda  
Ms. Rebekah Turner 
Ms. Aril Adiqu 
Ms. Alison Footman 
Ms. Adren Heathers 
Ms. Smita Wosh 
Ms. Ann Lamar 
Ms. Eva Margolies 
Mr. Bob Pratt 
Members of the Public  
Ms. Catherine Caims (Association of State and Territorial Health Officials) 
Ms. Candrea Cherry (Marshall Service) 
Ms. Denise Dodge (VA Department of Health) 
Dr. Michael Fleenor (Jefferson County Department of Health) 
Dr. Wendy Thanassi (Veterans Health Administration) 
Dr. Jennifer Flood (National Tuberculosis Controllers Association) 
Ms. Donna Wegner (National Tuberculosis Controllers Association) 
Mr. John Lozier (National Health Care for the Homeless Council) 
 
 
Advisory Council for the Elimination of Tuberculosis 
Centers for Disease Control and Prevention 
June 4 - 5, 2013   
81 
 





ACA Affordable Care Act  
ACET Advisory Council for the Elimination of Tuberculosis  
ACIP Association for Professionals in Infection Control and Epidemiology  
ACTG AIDS Clinical Trials Group  
AFB Acid-Fast Bacilli  
AIDAC Anti-Infective Drugs Advisory Committee  
AMA American Medical Association  
APHL Association of Public Health Laboratories  
ART Antiretroviral Therapy  
ASPR Assistant Secretary for Preparedness and Response 
ASTHO Association of State and Territorial Health Officials  
BCG Bacille Calmette-Guerin (vaccination)  
BMGF Bill and Melinda Gates Foundation 
BSC Board of Scientific Counselors  
CAPUS Care and Prevention in the United States  
CBO Community-Based Organization  
CDC Centers for Disease Control and Prevention  
CdV  Consultorios de Visa  
CEBSB Communications, Education, and Behavioral Studies Branch  
CGH Center for Global Health  
CITC Curry International Tuberculosis Center  
CMO Committee Management Office  
CPG Clinical Practice Guidelines  
CR Continuing Resolution  
CROI Conference on Retroviruses and Opportunistic Infections  
CSH Combat Support Hospital  
CTCA California Tuberculosis Controllers Association  
DASH Division of Adolescent and School Health  
DFO Designated Federal Officer  
DGDDER Division of Global Disease Detection and Emergency Response  
DGHA Division of Global HIV/AIDS  
DGMQ Division of Global Migration and Quarantine  
DHAP Division of HIV/AIDS Prevention  
DoD (United States) Department of Defense  
DOT directly observed therapy  
DR Dominican Republic  
DSTDP Division of STD Prevention  
DTBE Division of Tuberculosis Elimination  
DVH Division of Viral Hepatitis  
ECHPP Enhanced Comprehensive HIV Prevention Planning and Implementation 
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Program 
EIS Epidemic Intelligence Service  
EMR Electronic Medical Records  
FACA Federal Advisory Committee Act  
FBOP Federal Bureau of Prisons  
FDA (United States) Food and Drug Administration  
FOA Funding Opportunity Announcement  
FQ Fluoroquinolone 
FQHC Federally Qualified Health Center  
FY Fiscal Year  
GCC Global Communications Center  
GDD Global Disease Detection  
GDF Global Drug Facility  
GTBI New Jersey Medical School Global Tuberculosis Institute  
HAART Highly Active Antiretroviral Therapy  
HHS (United States) Department of Health and Human Services  
HICPAC Healthcare Infection Control Practices Advisory Committee  
HIV Human Immunodeficiency Virus  
HIV-
CAUSAL 
HIV Cohorts Analyzed Using Structural Approaches to Longitudinal Data  
HNTC Heartland National Tuberculosis Center  
HRSA Health Resources and Services Administration  
IAC International AIDS Conference  
ICE Immigration and Customs Enforcement  
ICU Intensive Care Unit  
IGRAs Interferon-Gamma Release Assays  
IHS Indian Health Service  
IND Investigational New Drug  
INH Isoniazid  
IOM Institute of Medicine  
IRB Institutional Review Board  
IRPB International Research and Programs Branch  
ISDA Infectious Diseases Society of America  
IT Information Technology  
LTBI Latent Tuberculosis Infection  
MAI Minority HIV/AIDS Initiative  
MASO Management Analysis and Services Office  
MDDR Molecular Detection of Drug Resistance (Service)  
MDR-TB Multidrug-resistant tuberculosis  
MMWR Morbidity and Mortality Weekly Report  
MOH Ministry of Health  
MSM Men who have sex with men  
Mtb Mycobacterium tuberculosis  
NAA Nucleic Acid Amplification  
NA-
ACCORD 
North American AIDS Cohort Collaboration on Research and Design  
 
 
Advisory Council for the Elimination of Tuberculosis 
Centers for Disease Control and Prevention 
June 4 - 5, 2013   
83 
NACCHO National Association of City and County Health Officials  
NCEZID National Center for Emerging and Zoonotic Infectious Diseases  
NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention  
NCIRD National Center for Immunization and Respiratory Diseases  
NGO Non-Governmental Organization  
NHANES National Health and Nutrition Examination Survey  
NHAS National HIV/AIDS Strategy  
NHCHC National Health Care for the Homeless Council 
NIAID National Institute of Allergies and Infectious Diseases  
NIH National Institutes of Health  
NIOSH National Institute for Occupational Safety and Health  
NMA National Medical Association  
NPRM Notice of Proposed Rule Making  
NTCA National Tuberculosis Controllers Association  
NTIP National Tuberculosis Indicators Project  
NTM Non-Tuberculous Mycobacteria  
NTNC National Tuberculosis Nurse Coalition 
NTP National Tuberculosis Program  
OADS Office of the Associate Director for Science  
OGAC Office of the US Global AIDS Coordinator  
OID Office of Infectious Diseases  
OMH Office of Minority Health  
OMHHE Office of Minority Health and Health Equity  
OSELS Office of Surveillance, Epidemiology, and Laboratory Services  
PAHO Pan American Health Organization  
PCSI Program Collaboration Service Integration  
PEPFAR President’s Emergency Plan for AIDS Relief  
PHAC Public Health Agency of Canada  
PHL Public Health Laboratory 
POW Prisoner of War  
PPD Purified Protein Derivative  
PPV Positive Predictive Value  
PZA Pyrazinamide  
QFT QuantiFERON-TB test  
RIPE Rifampin, Isoniazid, Pyrazinamide, and Ethambutol  
RTMCC Regional Training and Medical Consultation Centers  
RVCT Report of Verified Case of Tuberculosis  
RWJ Robert Wood Johnson (Foundation)  
SNTC Southeastern National Tuberculosis Center  
STD Sexually Transmitted Disease  
TAG Treatment Action Group  
TB Tuberculosis  
TB ETN Tuberculosis Education and Training Network  
TB PEN Tuberculosis Program Effectiveness Network  
TBRTMCCs Tuberculosis Regional Training and Medical Consultation Centers  
TBESC Tuberculosis Epidemiologic Studies Consortium  
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TBTC Tuberculosis Trials Consortium  
TST Tuberculin Skin Test  
TTI Tuberculosis Technical Instructions  
US United States  
USPSTF United States Preventive Services Task Force  
VA (United States) Department of Veterans Affairs  
VHA Veterans Health Administration 
WHO World Health Organization  
WTST Working Together to Stop TB  
XDR-TB Extensively Drug-Resistant Tuberculosis  
